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ABSTRACT 
Chapter 1: Introduction 
In the 1990’s a new paradigm in clinical practice emerged; evidence based-
medicine (EBM). This new process of systematically finding, appraising, and using 
research findings in clinical decision making, also required new ways of retrieving 
relevant studies from a growing body of literature in online medical databases, and 
synthesising the results of several studies on the same topic.  
For interventional medicine, EBM quickly revolutionised the way studies were 
reported, indexed in online databases, and meta-analysed. New guidelines for 
reporting controlled trials were developed, and indexers at the US National Library 
of Medicine began tagging randomised controlled trials with a unique “.rct” 
publication identifier. 
In contrast, the up-take of EBM principles in diagnostic medicine has been slow. 
Despite the publication of a statement for ‘Standards of Reporting Diagnostic 
Studies’ (STARD) in 2001, the quality of reporting diagnostic studies remains poor. 
Finding diagnostic studies in MEDLINE is difficult because no dedicated 
publication identifier exists, and often diagnostic studies on the same test are 
spread over a range of specialist journals.  
Methodologies for the systematic review and meta-analysis of diagnostic studies 
were also established much later than interventional studies, and rely on studies to 
provide conventional metrics of diagnostic test performance (sensitivity and 
specificity). While useful, these methods are of limited use when there is no 
reference standard test available.  
This thesis explores solutions to these problems within the framework of a specific 
clinical question: What is the best test for diagnosing latent tuberculosis in people 
undergoing solid organ transplant?  
 
Chapter 2: Efficient strategies to find diagnostic test accuracy studies  
In clinical practice there is often uncertainty about which tests to use and how to 
interpret their results. Diagnostic test accuracy studies can be used to answer 
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diagnostic questions, but finding them quickly in the MEDLINE database can be 
difficult, particularly in the clinical setting. While it possible to use ‘clinical queries 
limits’ (inbuilt search strategies in PubMed/ Ovid SP) to limit searches to 
diagnostic studies, other search strategies are also available and may perform 
better. The primary aim of the study presented in Chapter 2 was to evaluate the 
performance of published search strategies for diagnostic tests in nephrology 
journals. Nephrology journals were chosen because people with end stage kidney 
disease represent the majority of candidates for solid organ transplant. Our 
secondary aim was to determine if test performance had improved since the 
international publication of the ‘Standards for Reporting Diagnostic Accuracy 
Studies’ statement. We hypothesised that improved standards of publication may 
have led to improved reporting and indexing within MEDLINE, and hence 
improved search strategy performance. 
We hand-searched three prominent nephrology journals (the American Journal of 
Kidney Disease, The Journal of the American society for Nephrology, and Kidney 
International) between the years 2002-3 and 2009-10 for diagnostic accuracy 
studies. The studies identified formed a reference set, which were then used to 
evaluate the performance of fourteen published search strategies in terms of 
sensitivity, specificity and number needed to search. 
Our hand-search identified 103 diagnostic test accuracy studies, which formed 
2.1% of the total literature published. The most specific search strategy was the 
Haynes 2004 Narrow Clinical Queries limit (sensitivity: 0.20, 95%CI 0.13-0.29; 
specificity: 0.99, 95%CI 0.99-0.99). Using the Haynes 2004 Narrow Clinical 
Queries limit, a searcher would need to screen 3 (95%CI 2-6) articles from the 
search results to find one diagnostic study. Bachmann 2002 was the best-
balanced search strategy, which was sensitive (0.88, 95%CI 0.81-0.94), but also 
specific (0.74, 95%CI 0.73-0.75), with a number needed to screen of 15 (95%CI 
14-17). 
The Haynes 2004 Narrow Clinical Queries Limit (inbuilt into PubMed and Ovid SP) 
was the most specific search strategy, but identified only 20% of the total 
literature. To answer clinical questions about diagnostic tests in nephrology, 
clinicians may wish to consider using the Deville 2000 Balanced search strategy, 
which had similar specificity to the Haynes 2004 Clinical Queries Limit, but 
identified 57% of the total literature.  
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Chapter 3: Tests for latent tuberculosis in candidates for solid organ 
transplantation: a systematic review 
Tuberculosis is common infection in people undergoing solid organ transplantation 
due to increased risk of exposure to Mycobacterium tuberculosis bacteria and 
immunosuppression. The risk of developing tuberculosis after transplantation can 
be minimised with prophylactic drugs, but their toxic side-effects necessitate test-
directed treatment. Latent tuberculosis infections are difficult diagnose because 
bacteria cannot be cultured from sputum samples. The tuberculin skin test, and 
newer interferon gamma release assays measure the immune response to M. 
tuberculosis antigens, but their accuracy cannot be measured in conventional 
metrics of sensitivity and specificity because no reference standard test is 
available. Many studies have compared the results of the tuberculin skin test and 
interferon gamma release assays with clinical risk factors for tuberculosis as 
proxies for true infection. To synthesis the evidence presented by these studies we 
conducted a systematic review and meta-analysis of all studies that assessed the 
performance of a test for latent tuberculosis and reported risk factors for 
tuberculosis in people undergoing solid organ transplant. 
We identified 18 studies with data for meta-analysis. Both a positive tuberculin skin 
test and ELISA-based IGRA were strongly associated with clinical risk factors for 
TB (TST: OR 3.87; 95%CI 1.99-7.56, p<0.01, ELISA-based IGRA: OR 2.56; 
95%CI 2.56-5.27, p=0.01). A positive tuberculin skin test was also associated with 
radiological evidence of past TB (OR 3.18; 95%CI 1.76-5.76, p<0.01) and a history 
of contact with active TB (OR 3.24; 95%CI 1.13-9.29, p=0.03). A positive ELISA-
based IGRA was more likely to occur in participants who had received TB 
treatment (OR 22.31; 95%CI 7.80-63.76, p<0.01) or had diabetes. Few studies 
compared IGRAs with the tuberculin skin test head-to-head. No evidence of a 
difference in relative test performance was identified. 
Few studies were available to compare the performance of the TST and IGRAs. 
On best available evidence, either a TST or IGRA, or both can be used to 
diagnose latent TB in people undergoing solid organ transplant. This finding is 
congruent with current international guidelines for testing latent TB in 
immunosuppressed populations. 
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Chapter 4: Mismatch between risk of tuberculosis and testing practices in 
people being assessed for kidney transplantation 
In Australia, people on dialysis are ten times more likely to develop active 
tuberculosis than the general population. Current international guidelines 
recommend that all candidates for kidney transplant are screened for tuberculosis 
before transplantation. To determine whether testing practices in Australia meet 
current guidelines, we conducted a cross-sectional descriptive study of all people 
who underwent assessment for kidney transplant over a two-year period at a 
regional transplant centre. We searched hospital records, and collected data on 
the types of tests patients received, the test results, and clinical risk factors for 
latent tuberculosis.  
Two-hundred and one patients were assessed for kidney transplant. Patients had 
a mean age of 50.8 ±12.6 years, 63.7% were male and 22.9% had been BCG 
vaccinated. The most frequent cause of kidney failure was diabetic nephropathy 
(29.4%). At least one risk factor for latent TB, other than chronic kidney disease, 
was present in 49.8% of patients. The most prevalent risk factors for latent TB 
were high-risk country of birth (29.4%), diabetes mellitus (27.4%), and prior 
immunosuppression (20.9%). Forty seven patients (23.4%) were tested for latent 
TB. Of patients with at least one risk factor for latent TB, only 37.0% were tested. 
Thirteen (35.1%) of the 37 people with risk factors for TB and were tested, 
returned a positive result. 
Despite a high prevalence of risk factors for tuberculosis in candidates for kidney 
transplant, few patients were tested. These data indicate an unawareness of 
current guidelines amongst transplant staff in Australia and demonstrate the need 
for a nation-wide screening protocol. 
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Context of this thesis 
My interest in diagnostic medicine developed from my background in immunology 
and pathology as a basic scientist, and the dilemmas around diagnostic testing 
that arose during my post-graduate training as a clinical epidemiologist. After 
finishing my training, I began working at the Centre for Kidney Research (The 
Children’s Hospital at Westmead) on a systematic review examining the evidence 
of testing for latent tuberculosis in people with end-stage kidney disease (see 
Appendix A). This review compared the performance of new interferon gamma 
release assays to the old tuberculin skin test using novel methodology for 
assessing test performance in the absence of a reference standard. Through this 
project I became interested in how clinicians use diagnostic evidence from the 
literature and apply it to their clinical practice using evidence-based principles.  
Developing the clinical themes of this thesis 
The use of diagnostic tests is central to the practice of modern medicine, but 
knowing which test to use, and when, can be problematic. To make evidence-
based diagnoses, clinicians need efficient ways of (1) accessing diagnostic 
studies, (2) interpreting the results of several studies, and (3) checking the 
applicability of studies to their own setting. The aim of this thesis is to explore 
solutions to these problems by addressing a specific clinical question; What is the 
best screening test for latent tuberculosis in patients undergoing transplantation? 
This chapter presents background information on how I developed my clinical 
questions, how diagnostic tests are currently used in the Australia, and the 
epidemiology of latent tuberculosis in transplantation. Chapter 2 presents evidence 
on the performance of methodological filters designed to find diagnostic studies in 
MEDLINE, with a focus on specialist nephrology journals. Chapter 3 presents the 
results of a systematic review and meta-analysis of tests for latent tuberculosis in 
solid organ transplantation. Chapter 4 presents the results of a cross-sectional 
study on the prevalence of risk factors for latent tuberculosis, and testing practices 
used to diagnose latent TB, in candidates for kidney transplant in Australia. There 
is no formal ‘literature review’ chapter, as Chapters 2-3 systematically review key 
questions around this topic. Thus, this thesis comprises a mixture of 
methodological and of clinical content research.  
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Evidence-based testing is underutilised in Australia 
Diagnostic tests play an integral role in all aspects of medical decision making, but 
surprisingly, little is known about their utilisation and cost in the Australian setting.  
We know that test usage is high, with approximately 9.25 million hospital inpatient 
diagnoses made in between 1993 to 20121. We also know that a high proportion of 
testing is probably unnecessary; one study of hospital emergency department 
found that 40% of testing could be reduced by educating staff and introducing 
protocols for test ordering2. Unnecessary testing is not just a burden on the health 
budget, it can also be harmful. Over-screening in the cancer setting is well-
documented. For some cancers, the psychological effects of labelling patients with 
disease, and the invasive nature of some diagnostic procedures outweigh any 
advantage of diagnosis3. On the other hand, missed or misdiagnosis can also be 
harmful. An audit of the United States National Practitioner Data Bank revealed 
that approximately 40-80,000 deaths occur each year due to misdiagnosis, and 
that 5% of all autopsies reveal avoidable diagnostic errors4. While no data on the 
potential morbidity and mortality of misdiagnosis in Australia exist, from 2010-11 
diagnostic errors made up 26.5% of public sector compensation claims5. Over-
testing and misdiagnosis can be reduced by using evidence-based practices. For 
clinical questions about the performance and interpretation of diagnostic tests, the 
best form of primary research evidence is a diagnostic test accuracy study, and 
best of all a systematic review and meta-analysis of these studies. In order to 
make evidence-based decisions with information derived from diagnostic test 
studies, clinicians require efficient ways to access studies from online medical 
databases, and to appraise and interpret the results of several studies on the 
same test and population.  
 
Finding relevant diagnostic studies in online databases is difficult 
The MEDLINE database contains of over 21 million references to journal articles 
published between 1946 and the present day. Finding relevant diagnostic studies 
is problematic, because studies about the same test are often published in diverse 
population, methodology and disease specific journals. Each journal article 
indexed in MEDLINE is allocated a publication type and Medical Subject Headings 
(MeSH) by staff at the US National Library of Medicine. MeSH is a hierarchal, well-
defined vocabulary of terms that provide a consistent way of retrieving studies 
Chapter 1: Introduction 
 4 
from MEDLINE. Similarly, studies may also be retrieved using a specific 
publication type. Unlike randomised controlled trials, which have a specific “.rct” 
publication type in MEDLINE, no publication type for diagnostic studies is 
available. Diagnostic studies must therefore be located using MeSH terms and text 
words, a method which is often hampered by poor reporting of studies by authors, 
and suboptimal indexing by the US National Library of Medicine. A recent review 
of diagnostic studies in nephrology found that the standard of reporting diagnostic 
accuracy studies had not increased over past 30 years, despite the publication of 
a Standards of Reporting Diagnostic Studies consensus statement in 20016. To 
find diagnostic studies quickly and efficiently, many medical specialties have 
developed search strategies designed to reduce the number of search results 
when searching for diagnostic accuracy studies. By increasing search specificity, 
these search strategies should allow clinicians to access evidence for diagnostic 
test performance quickly in the clinical setting. However, little is actually known 
about the performance of these search strategies in the chronic kidney disease 
and transplant setting. Chapter 1 presents the results of an investigation into the 
performance of search strategies for diagnostic studies in nephrology journals. 
 
The epidemiology of tuberculosis is different in people undergoing solid 
organ transplantation 
In the general population the life-time risk of reactivation of latent tuberculosis 
infection is 5-10%, but the risk in transplant populations is 20-74 times higher7. 
The reasons for increased risk may be the use of immunosuppressive drugs to 
prevent rejection, as well as infections acquired from donated organs, underlying 
chronic kidney disease, and chronic liver disease. Transplant recipients are also 
more likely to die from active tuberculosis, with a mortality rate of 19-40%, over 10 
fold higher than the general population7. In Australia, the annual incidence of 
active tuberculosis in people on dialysis, including potential kidney transplant 
recipients, was 67 cases per 100,000 people, some 10 times higher than the 
general population rate. More dialysis patients were also from high risk countries 
of birth of birth (≥100 cases per 100,000) compared to the general population8.  
The complex pathogenesis of tuberculosis limits our ability to diagnose 
tuberculosis in immunosuppressed people, including transplant recipients. After 
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initial colonisation of the host, the causative agent of tuberculosis (Mycobacterium 
tuberculosis) is typically encased in granulomatous tissue by the host immune 
system, usually within the lungs. Decreased oxygen availability within the 
granuloma induces dormancy in the bacteria, which corresponds clinically with an 
asymptomatic period of latency. While granulomatous tissue quarantines the 
bacteria and prevents pathogenesis, crucially, it also prevents testing by in vitro 
culture. Tests for latent tuberculosis, including the tuberculin skin test and 
interferon-γ release assays measure the host immune response to tuberculosis 
antigens, but without the ability to culture bacteria from latently infected people, it 
is difficult to evaluate their diagnostic performance.  
New methodologies are needed to assess the performance of tests for latent 
tuberculosis in transplant patients 
The conventional method for assessing the diagnostic performance of a new test, 
is to compare new test results against a reference standard test (also referred to 
as a gold-standard test) in a defined population. This method assumes the 
reference standard test is a perfect discriminator of people that have disease, and 
those that don’t. Using this method, test performance is calculated in metrics of 
sensitivity (the proportion of people with disease that are correctly identified) and 
specificity (the proportion of people without disease that are correctly identified). 
Sensitivity and specificity are useful metrics in evidence-based medicine because 
given a defined pre-test probability of disease, they can be used calculate the 
absolute risk of disease after testing. But what happens when no reference 
standard test is available, as is often the case when a new test is introduced to 
replace an old test? In the diagnosis of latent tuberculosis, the tuberculin skin test 
(or Mantoux test) has been in used for over 100 years and has well-described 
deficiencies as a reference standard test. Newer tests, the interferon-gamma 
release assays, measure the T-cell mediated response of the host immune system 
to tuberculosis antigens. Interferon-γ release assays are thought to be superior to 
the tuberculin skin test because they utilise a control for the immune response and 
do not display cross-reactivity with the Bacille Calmete-Guérin vaccination. 
Without a reference standard test, the accuracy of interferon-γ release assays 
cannot be assessed by conventional epidemiological methods. To overcome this 
challenge, some studies have evaluated tests for latent tuberculosis using clinical 
risk factors for tuberculosis a proxy reference standard for latent tuberculosis. 
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Chapter 3 of this thesis systematically reviews these studies and presents a meta-
analysis of their results.  
Test performance may vary with prevalence of tuberculosis 
The utility of latent tuberculosis testing at an institutional level depends on whether 
the benefits of identifying and treating cases of tuberculosis outweigh the 
complications of treatment in patients who test falsely positive. If the underlying 
prevalence of latent tuberculosis is low, then a test may be of limited value for 
preventing tuberculosis, but could generate high volumes of unnecessary 
treatment. Anti-tuberculosis drugs can unpredictably affect the bio-availability of 
immunosuppressive drugs used to prevent rejection after transplant, as well cause 
neurotoxicity and hepatotoxicity. This particularly problematic for liver transplant 
candidates, who may have little residual liver function. Data collected by the World 
Health Organisation suggests that significant variation in the prevalence 
tuberculosis exists around the world9. In Chapter 4 we sought to determine 
whether the findings from our systematic review presented in Chapter 3 were 
applicable to our own clinical setting; a major regional centre for kidney transplant. 
Chapter 4 presents the results of a cross-sectional study on the prevalence of risk 
factors in candidates for kidney transplantation, and testing practices used to 
diagnose latent TB, over a two-year period at our centre. 
Chapter 1: Introduction 
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2.1: Abstract 
Background: Nephrologists looking for quick answers to diagnostic clinical 
questions in MEDLINE can use a range of published search strategies or Clinical 
Query limits to improve the precision of their searches. We aimed to evaluate 
existing search strategies for finding diagnostic test accuracy studies in 
nephrology journals.  
Study design: Cross sectional analytic study. 
Setting and participants: Diagnostic studies published in the American Journal of 
Kidney Disease, the Journal of the American Society for Nephrology, and Kidney 
International (KI) in 2002-3 and 2009-10.  
Index tests: Fourteen published search strategies for diagnostic studies were 
used in MEDLINE with terms to restrict search results to the journals and years of 
interest. 
Reference standard: Two investigators independently hand searched the same 
journals to create a reference set of diagnostic test accuracy studies.  
Results: We identified 103 diagnostic test accuracy studies, accounting for 2.1% 
of all studies published. The most specific search strategy was the Haynes 2004 
Narrow Clinical Queries limit (sensitivity: 0.20, 95%CI 0.13-0.29; specificity: 0.99, 
95%CI 0.99-0.99). Using the Haynes 2004 Narrow Clinical Queries limit, a 
searcher would need to screen 3 (95%CI 2-6) articles from the search results to 
find one diagnostic study. The most sensitive search strategy was van der Weijden 
1999 Extended (sensitivity: 0.95; CI 0.89-0.98; specificity 0.55, 95%CI 0.53-0.56), 
but required a searcher to screen 24 (95%CI 23-26) articles to find one diagnostic 
study. Bachmann 2002 was the best-balanced search strategy, which was 
sensitive (0.88, 95%CI 0.81-0.94), but also specific (0.74, 95%CI 0.73-0.75), with 
a number needed to screen of 15 (95%CI 14-17). 
Limitations: Given the low number of diagnostic studies published in nephrology 
journals, estimates of sensitivity were imprecise. 
Conclusions: Diagnostic studies are infrequently published in nephrology 
journals. The addition of a strategy for diagnostic studies to a subject search 
strategy in MEDLINE may reduce the volume of records needed to screen, whilst 
preserving adequate search sensitivity for routine clinical use.    
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2.2: Background 
The use of diagnostic tests is central to the practice of modern medicine, but 
knowing which test to use, and when, can be problematic. Each year in the United 
States an estimated 40-80,000 deaths occur due to misdiagnosis, and 5% of all 
autopsies reveal avoidable diagnostic errors1. Information provided by diagnostic 
tests must be accurate for clinicians to make evidence based decisions about 
treatment2. Often several diagnostic tests can be used for the same disease, and 
to determine which test is more accurate for a given clinical situation, clinicians 
must base their decisions on information from published diagnostic test accuracy 
(DTA) studies.  
Finding relevant published studies can be time consuming, and most search 
strategies identify a mix of useful and less useful papers. A comprehensive 
literature search is often not a realistic option for nephrologists in the time-
pressured clinical setting. Nephrologists conducting searches for diagnostic 
studies in MEDLINE have the option of adding an automated Clinical Queries limit 
or a methodological search strategy to their subject search strategy to improve 
search efficiency. The Clinical Queries limits for diagnosis in MEDLINE use search 
terms for diagnostic studies developed by Haynes et al in 20043. The Haynes 
search strategies were developed and validated in a set of MEDLINE records from 
a diverse range of medical specialties3. For ease of use, the Clinical Queries limits 
for diagnosis have been integrated into the user interfaces of the PubMed and 
OvidSP search portals for MEDLINE. Searchers may select either a broad (more 
sensitive) or narrow (more specific) search strategy to suit the purpose of their 
search. A precise (best balance of sensitivity and specificity) search strategy is 
also available in OvidSP. The Clinical Queries limits for diagnosis have a reported 
sensitivity and specificity in MEDLINE of 98% and 78% respectively for the broad 
option, and 64% and 98% respectively for the narrow option4. 
In addition to the integrated Clinical Queries limits for MEDLINE, several other 
search strategies have been developed for finding diagnostic studies within 
particular medical disciplines, as well as the MEDLINE database more generally3,5-
9. The reported sensitivities and specificities of search strategies for diagnostic 
studies in MEDLINE range from 31-98.8% and 73-99% respectively, suggesting 
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they may perform as well, or better, than the current Clinical Queries limits for 
diagnosis3,5-9.  
The best search strategy for finding diagnostic studies in specialist nephrology 
journals is currently unknown. We hypothesised that the performance of published 
search strategies may behave differently in nephrology journals because the 
prevalence of DTA studies is lower and authors’ methodological reporting is 
poorer, causing unreliable indexing in MEDLINE10. The primary aim of this study 
was to characterise the performance of methodological search strategies for 
diagnostic studies in nephrology journals. Our secondary aim was to compare the 
performance of search strategies for diagnostic studies before and after the 
publication of an international statement of STAndards for Reporting Diagnostic 
accuracy studies (STARD)11. We hypothesised that the STARD reporting 
guidelines may have led to an improvement in the performance of the search 
strategies through improvements in the way DTA studies were reported by authors 
and indexed within MEDLINE. 
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2.3 Methods 
Reference set 
Two reviewers independently searched by hand the 2002, 2003, 2009 and 2010 
issues (excluding supplements) of three major general nephrology journals for 
diagnostic accuracy studies; the American Journal of Kidney Diseases (AJKD), the 
Journal of the American Society of Nephrology (JASN), and Kidney International 
(KI). We defined a DTA study as any study that assessed the accuracy of one or 
more index tests against a reference standard, for detecting the presence of a 
disease or measuring a physiological parameter of a disease. Any disagreements 
were resolved by discussion, and if necessary, arbitration with a third reviewer. We 
extracted study data on the target condition, index test, reference standard test 
and study population using a standardised data extraction form. To locate the 
included studies in MEDLINE we constructed a search strategy composed of 
unique article identifier numbers.  
Search strategy performance 
We assessed the accuracy of fourteen published methodological search strategies 
for DTA studies in MEDLINE3,5-9. See Supplementary Table 2.3 for OvidSP search 
strategy syntax. Search strategies were combined with terms to limit the search 
results to the journals of interest, the years 2002-3 and 2009-10, and to exclude 
articles from supplement issues. Using hand searching as the reference standard, 
we generated a cross-classification table for each search strategy, recording which 
DTA studies were identified by the search strategy and which were not.  
Statistical methods 
For each search strategy we calculated the sensitivity, specificity, precision and 
number needed to search with 95% confidence intervals from cross-classification 
tables comparing search strategy results and our hand searched reference set. 
Sensitivity was defined as the proportion of all DTA studies that were correctly 
identified by the search strategy. Specificity was defined as the proportion of all 
non-DTA studies that were correctly identified by the search strategy. Precision 
was defined as the proportion of all studies correctly identified as DTA or non-DTA 
by the search strategy. The number needed to search was defined as the average 
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number of records that needed to be searched to locate one DTA study. The 
number needed to search was calculated by dividing the total number of records 
returned by the search strategy by the number of DTA studies found. An exact 
McNemar’s test at the p<0.05 significance level was conducted to compare the 
specificity and sensitivity of search strategies with similar performance 
characteristics. We also compared the sensitivity, specificity and precision of 
search strategies between 2002-3 and 2009-10 using the Chi-Square test at a 
significance level of p<0.05.
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2.4: Results 
The results of our hand search are presented in Figure 2.1. We hand searched 
4908 journal articles and identified 103 DTA studies; 48 (47%) from AJKD, 17 
(17%) from JASN; and 38 (37%) from KI. 
Characteristics of DTA studies   
The DTA studies identified in our hand search were highly diverse in patient 
population, the type of test assessed and target condition diagnosed. DTA study 
characteristics are summarised in Table 2.1. Of the 103 DTA studies, most were 
conducted in dialysis patients (37, 36%), assessed either biochemistry (34, 33%) 
or clinical algorithm based tests (19, 18%), and tests that assessed kidney function 
(30, 29%) or dialysis delivery (19, 18%). 
Methodological search strategy performance 
The performance of all search strategies are summarised in Figure 2.2 and Table 
2.2. The van der Weijden 1997 Extended search strategy had the highest 
sensitivity in the 2002-3 period (0.95; 95%CI 0.86-0.99), the 2009-10 period (0.95; 
95%CI 0.85-0.99), and overall (0.95; 95%CI 0.89-0.98). The overall precision of 
the van der Weijden 1997 Exended search strategy was 0.55 (95%CI 0.54-0.57) 
and the mean number of studies needed to screen to find one DTA study was 24 
(95%CI 23-26). The Haynes 2004 Narrow search strategy was the most specific 
search strategy, with an overall specificity of 0.99 (95%CI 0.99-0.99) and was also 
the most precise search strategy, with an overall precision of 0.97 (95%CI 0.0.97-
0.98). The Haynes 2004 Narrow search strategy reduced the number needed to 
screen to 3 (95%CI 2-6). Visual inspection of the receiver operator curve (Figure 
2.3) revealed two best-balanced search strategies; Bachmann 2002 and van der 
Weijden 1997 Short. Bachmann 2002 had a sensitivity of 0.88 (95%CI 0.81-0.94) 
and a specificity of 0.74 (95%CI 0.73-0.75), and reduced the number needed to 
search to 15 (95%CI 14-17). The sensitivity of the Bachmann 2002 and van der 
Weijden 1997 Extended and search strategies were not statistically different (χ2 = 
2.4, p=0.12). The van der Weijden 1997 Short strategy had a sensitivity of 0.76 
(95%CI 0.66-0.84) and a specificity of 0.84 (95%CI 0.83-0.85). Using the van der 
Weijden Short strategy reduced the number needed to search to 12 (95%CI 10-
14). 
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Change in strategy performance over time 
Comparing the sensitivity of search strategies between 2002-3 and 2009-10 we 
observed significant increases in the sensitivity of two search strategies. The 
Haynes 2004 Broad search strategy increased in sensitivity by 0.22 (95%CI 0.06-
0.38, p=0.01) to 0.86 (95%CI 0.73-0.95), but decreased in specificity by 0.05 
(95%CI 0.03-0.07, p<0.001) to 0.78 (95%CI 0.76-0.80). The Vincent 2003 Broad 
search strategy increased in sensitivity by 0.17 (95%CI 0.03-0.32, p=0.03) to 0.89 
(95%CI 0.75-0.96), with no significant decrease in specificity. We observed small 
but statistically significant increases in the specificity of three search strategies; 
the Haynes 2004 Balanced strategy increased in specificity by 0.01 (95%CI 0.00-
0.03, p=0.03) to 0.92 (95%CI 0.91-0.93), the Haynes 1994 Balanced strategy 
increased in specificity by 0.03 (95%CI 0.00-0.06, p=0.03) to 0.61 (95%CI 0.59-
0.63), and the Haynes 2004 Narrow strategy increased in specificity by 0.01 
(95%CI 0.00-0.01, p=0.03) to 0.99 (95%CI 0.99-1.00). The Bachmann 2002 
search strategy decreased in specificity by 0.07 (95%CI 0.04-0.09, p<0.001) to 
0.70 (95%CI 0.68-0.72). See Supplementary Tables 2.1-2.2 for detailed 
performance characteristics of search strategies in the 2002-3 and 2009-10 time 
periods.
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2.5: Discussion 
To answer questions about diagnostic tests, nephrologists wishing to access 
current research are able to search MEDLINE using methodological search 
strategies or inbuilt Clinical Queries limits. This study found that in the context of 
specialist nephrology journals, a clinician using a methodological search strategy 
for DTA studies could reduce the volume of records that need to be screened 
whilst preserving adequate search sensitivity for routine clinical use.  
 
The ideal methodological search strategy depends on the purpose for which a 
search is being conducted. A narrow search strategy is best suited to quick point-
of-care searches that require immediate answers. Our results revealed that the 
most specific search strategy in the context of nephrology journals was Haynes 
2004 Narrow. The Haynes 2004 Narrow strategy reduced the number needed to 
search to just three articles. Haynes 2004 Narrow is also a Clinical Queries limit in 
OvidSP and PubMed, allowing nephrologists to access it quickly and easily in the 
clinical setting. Problematically however, the Haynes 2004 Narrow strategy missed 
80% of total DTA studies. The Deville 2000 Broad, Deville 2000 Balanced, Haynes 
2004 Balanced, and Vincent 2003 Narrow search strategies demonstrated high 
specificities comparable to the Haynes 2004 Narrow strategy, but also had fair 
sensitivity (0.55-0.59), see Figures 2.2-2.3. Clinicians may also wish to consider 
these search strategies for narrow searches. 
 
For more comprehensive searches, a broad (highly sensitive) search strategy is 
required. Broad search strategies allow the searcher to capture most of the 
available relevant studies, but may also include many irrelevant studies. A broad 
search strategy would be most useful to a clinician worried about missing relevant 
studies and with sufficient time to screen search results. Overall, the van der 
Weijden 1997 Extended search strategy was the most sensitive, capturing 95% of 
all relevant literature while offering a modest (50%) reduction in the number 
needed to search. Using the van der Weijden 1997 Extended strategy, an 
investigator would need to screen an average of 24 studies to find one DTA study. 
We found no significant difference between the sensitivity of the van der Weijden 
Extended and Bachmann 2002 search strategy, and therefore clinicians may also 
wish to us the Bachmann 2002 strategy in sensitive searches. 
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A best-balanced search strategy provides the best trade-off between reduction in 
sensitivity and gain in specificity. We identified two comparable best-balanced 
search strategies; Bachmann 2002, which captured 88% of all DTA studies and 
reduced the number needed to search by 70% to an average of 15, and van der 
Weijden 1997 Short strategy, which captured 76% of DTA studies and reduced the 
number needed to search to 12. A best-balanced search strategy may be useful 
when both sensitivity and specificity of the search are important, but a compromise 
must be made between capturing all DTA studies and reducing the workload of the 
search.  
 
Due to the small number of diagnostic studies identified in our journal set, this 
study lacked the statistical power to detect increases in the sensitivity of search 
strategies between 2002-3 and 2009-10. Overall we observed a general trend 
toward increasing sensitivity of search strategies, but only two increases (Haynes 
2004 broad and Vincent 2003) were statistically significant. We also observed 
small but statistically significant increases in the specificity of three search 
strategies (Haynes 2004 balanced, Haynes 1994 balanced, and Haynes 2004 
narrow). The observed increases in the performance of search strategies between 
2002-3 and 2009-10 may represent better standards of reporting diagnostic 
studies by authors, following the publication of the STARD statement.  
 
In addition to nephrology journals, DTA studies in people with kidney disease may 
also be published in test or target condition-specific journals. Garg et al showed 
that nephrology-related information is spread across a wide range of journals, 
including general medicine, transplantation and urology journals12. For example, a 
study assessing the performance of computed tomography for detecting renal 
carcinoma in dialysis patients may be published in a nephrology journal, a nuclear 
medicine journal or a cancer journal. The search strategy performance estimates 
derived in this study may not be applicable to these journals. Also cause for 
concern was the underrepresentation of DTA studies conducted in transplant 
patients in our reference set. Kidney transplant recipients are a major subgroup of 
kidney disease patients, however in our study only 8 (7.8%) of DTA studies were 
conducted in this population. It is likely that DTA studies conducted in kidney 
transplant patients are preferentially published in transplant journals rather than 
nephrology journals.  
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The application of methodological search strategies to clinical searches has the 
potential to substantially reduce the burden of manual record screening, whilst 
maintaining search sensitivity adequate for routine clinical use. However, care 
must be taken to ensure the performance characteristics of the search strategy 
chosen are appropriate for the purpose of the search. Future research in this area 
should focus on assessing the performance of diagnostic search strategies in 
record sets derived from relevant systematic reviews. Taking advantage of quality 
assessments performed in existing systematic reviews, a future study could 
compare the quality of DTA studies captured and missed by search strategies. If 
studies missed by search strategies are consistently poor quality, the trade-off in 
reduced sensitivity for reduced number needed to search is advantageous.
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Figure 2.1 Process for identification of diagnostic test accuracy studies 
(reference set) 
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Figure 2.2: Sensitivity and specificity of search strategies for locating DTA 
studies
Study
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Figure 2.3: Receiver operator curve of performance characteristics of search 
strategies  
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Table 2.1: Characteristics of diagnostic test accuracy studies  
 
Characteristic 
 2002-3 
n (%) 
 2009-10 
n (%) 
Overall 
n (%) 
Journal 
Total 59 (100) 44 (100) 103 (100) 
American Journal of 
Kidney Disease 
31 (53) 17 (39) 48 (47) 
Journal of the American 
Society of Nephrology 
8 (14) 9 (21) 17 (17) 
Kidney International 20 (34) 18 (41) 38 (37) 
Type of test (based on index test) 
Biochemistry 18 (31) 16 (36) 34 (33) 
Clinical 8 (14) 6 (14) 14 (14) 
Imaging 11 (19) 2 (5) 13 (13) 
Diagnostic algorithm 8 (14) 11 (25) 19 (18) 
Dialysis related 6 (10) 6 (14) 12 (12) 
Other‡ 8 (14) 3 (7) 11 (11) 
Population (excluding healthy controls) 
Dialysis 30 (51) 7 (19.0) 37 (35.9) 
Transplant 2 (3) 6 (75.0) 8 (7.8) 
Chronic kidney disease 4 (7) 5 (55.6) 9 (8.7) 
Acute kidney injury 3 (5) 5 (62.5) 8 (7.8) 
General population 3 (5) 4 (57.1) 7 (6.8) 
Diabetics 6 (10) 3 (33.3) 9 (8.7) 
Other† 11 (19) 14 (56.0) 25 (24.3) 
Target Condition 
Kidney function 14 (46.7) 16 (53.3) 30 (29.1) 
Dialysis delivery 16 (84.2) 3 (15.8) 19 (18.4) 
Cardiovascular diseases 10 (83.3) 2 (16.7) 12 (11.7) 
Kidney injury 2 (20.0) 8 (80.0) 10 (9.7) 
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Metabolic bone diseases 6 (85.7) 1 (14.3) 7 (6.8) 
CKD symptoms 4 (66.7) 2 (33.3) 6 (5.8) 
Inherited kidney 
diseases 
2(33.3) 4 (66.7) 6 (5.8) 
Other* 5 (38.5) 8 (61.5) 13 (12.6) 
 
*Other: Allograft rejection, psychological disorders, infectious diseases, diabetes, and kidney 
diseases 
‡Other: Genetic, microbiology, haematology, endocrinology, histopathology,   
†Other: Renal clinic patients, hospitalised patients, cardiothoracic surgery, polycystic kidney 
disease, unidentified renal disease, proteinuria, liver transplant candidates  
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Table 2.2: Search strategy performance in a hypothetical set of 5000 
publications with a 2% prevalence of diagnostic test accuracy studies 
 
 
Search strategy 
 DTA study prevalence = 2%, N=5000 
DTA studies 
(N=100) 
Records to search to identify 
one DTA study (95%CI) 
Captured Missed 
van der Weijden 1997 
(Extended) 
95 5 24 (23-26) 
Bachmann 2002 88 12 15 (14-17) 
Haynes 1994 (Best balance) 86 14 24 (22-27) 
Vincent 2003 (Broad) 79 21 24 (22-28) 
van der Weijden 1997 (Short) 76 24 12 (10-14) 
Haynes 2004 (Broad) 74 26 14 (12-16) 
Haynes 1994 (Broad) 73 27 26 (22-30) 
Deville 2000  (Broad) 59 41 6 (5-8) 
Vincent 2003 (Narrow) 59 41 6 (5-8) 
Haynes 2004 (Best balance) 43 57 7 (6-9) 
Deville 2000 (Best balance) 55 45 5 (4-6) 
Deville 2000 (Narrow) 43 57 6 (4-8) 
Haynes 1994 (Narrow) 38 62 6 (5-9) 
Haynes 2004 (Narrow) 20 80 3 (2-6) 
Chapter 2: Efficient strategies to find diagnostic test accuracy studies 
28 
 
Supplementary figure 2.1: Sensitivity and specificity of search strategies for the years 2002-3 
Study
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Ex: Extended, Sh: Short, TP: True Positive, FP: False Positive, FN: False Negative, TN: True Negative 
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Supplementary figure 2.2: Sensitivity and specificity of search strategies for the years 2009-10 
Study
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Ex: Extended, Sh: Short, TP: True Positive, FP: False Positive, FN: False Negative, TN: True Negative
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Supplementary Table 2.3: OvidSP search syntax 
 
Search strategy OvidSP syntax 
Bachmann 2002 
1. exp "Sensitivity and Specificity"/ 
2. predict$.tw. 
3. diagnos$.tw. 
4. di.fs. 
5. du.fs. 
6. accura$.tw. 
7. or/1-6 
 
Deville 2000  (Broad) 
1. exp "Sensitivity and Specificity"/ 
2. specificity.tw. 
3. false negative.tw. 
4. accuracy.tw. 
5. screening.tw. 
6. or/1-5 
 
Deville 2000 (Best balance) 
1. exp "Sensitivity and Specificity"/ 
2. specificity.tw. 
3. false negative.tw. 
4. accuracy.tw. 
5. or/1-4 
 
Deville 2000 (Narrow) 
1. exp "Sensitivity and Specificity"/ 
2. specificity.tw. 
3. false negative.tw. 
4. or/1-3 
 
Haynes 2004 (Broad) 
1. sensitiv$.mp. 
2. diagnos$.mp. 
3. di.fs. 
4. or/1-3 
 
Haynes 2004 (Best balance) 
1. sensitiv$.mp. 
2. predictive value$.mp. 
3. accurac$.tw. 
4. or/1-3 
Haynes 2004 (Narrow) 1. specificity.tw. 
Haynes 1994 (Broad) 
1. exp "Sensitivity and Specificity"/ 
2. di.xs. 
3. du.fs. 
4. sensitivity.tw. 
5. specificity.tw. 
6. or/1-5 
 
Haynes 1994 (Best balance) 
1. exp "Sensitivity and Specificity"/ 
2. exp Diagnosis/ 
3. du.fs. 
4. specificity.tw. 
5. (predictive and value$).tw. 
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6. or/1-5 
 
Haynes 1994 (Narrow) 
1. exp "Sensitivity and Specificity"/ 
2. (predictive and value$).tw. 
3. or/1-2 
 
Vincent 2003 (Broad) 
1. exp "sensitivity and specificity"/ 
2. (sensitivity or specificity or accuracy).tw. 
3. ((predictive adj3 value$) or (roc adj curve$)).tw. 
4. ((false adj positiv$) or false negativ$).tw. 
5. ((observer adj variation$) or (likelihood adj3 
ratio$)).tw. 
6. likelihood function/ 
7. exp mass screening/ 
8. diagnosis, differential/ or exp Diagnostic errors/ 
9. di.xs. or du.fs. 
10. or/1-9 
 
Vincent 2003 (Narrow) 
1. exp "Sensitivity and Specificity"/ 
2. (sensitivity or specificity or accuracy).tw. 
3. ((predictive adj3 value$) or (roc adj curve$)).tw. 
4. ((false adj positiv$) or (false adj negativ$)).tw. 
5. (observer adj variation$).tw. 
6. likelihood function/ 
7. exp Diagnostic Errors/ 
8. (likelihood adj3 ratio$).tw. 
9. or/1-8 
 
van der Weijden 1997 (Extended) 1. exp Diagnosis/di [Diagnosis] 
2. Diagnosis Differential/ 
3. exp "Sensitivity and Specificity"/ 
4. Reference Values/ 
5. False Negative Reactions/ 
6. False Positive Reactions/ 
7. exp Mass Screening/ 
8. or/1-7 
9. diagnos$.tw. 
10. (sensitivity or specificity).tw. 
12. predictive value$.tw. 
13. reference value$.tw. 
14. ROC.tw. 
15. likelihood ratio$.tw. 
16. monitoring.tw. 
17. or/9-16 
18. or/8,17 
 
van der Weijden 1997 (Short) 1. exp Diagnosis/ 
2. exp "Sensitivity and Specificity"/ 
3. Reference Values/ 
4. False Negative Reactions/ 
5. False Positive Reactions/ 
6. exp Mass Screening/ 
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7. or/1-7 
8. diagnos$.tw. 
9. (sensitivity or specificity).tw. 
10. predictive value$.tw. 
11. reference value$.tw. 
12. ROC.tw. 
13. likelihood ratio$.tw. 
14. monitoring.tw. 
15. or/8-14 
16. or/7,15 
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3.1: Abstract 
Transplant recipients with latent tuberculosis (TB) are at high risk of developing 
active TB. Active TB can be prevented with chemoprophylaxis, but latent TB must 
first be identified. The most accurate test for diagnosing latent TB in candidates for 
organ transplantation is uncertain. We conducted a systematic review and meta-
analysis to assess the relative test performance of interferon gamma release 
assays (IGRAs) and the tuberculin skin test (TST) in people undergoing solid 
organ transplantation. Test performance was measured as a diagnostic odds ratio 
(OR), with a positive odds defined as the odds of a positive test in the presence of 
a clinical risk factor (used as a proxy for the presence of TB). We identified 18 
studies with data, including eight studies that compared an IGRA with the TST 
directly, and 10 studies that evaluated only the TST. Both a positive tuberculin skin 
test and IGRA were strongly associated with clinical risk factors for TB (TST: OR 
3.87; 95%CI 1.99-7.56, p<0.01, IGRA: OR 2.56; 95%CI 1.24-5.27, p=0.01), and 
radiological evidence of past TB (TST: OR 3.18; 95%CI 1.76-5.76, p<0.01, IGRA: 
OR 2.56; 95%CI 1.69-3.88, p<0.01). Due to limited data, estimates of relative 
performance of IGRAs and TST were imprecise. Test superiority was uncertain for 
clinical risk factors (relative OR: 0.65; 95%CI 0.36-1.18, p=0.15), radiological 
evidence of TB (relative OR: 1.09; 95%CI 0.22-5.35, p=0.92), diabetes (relative 
OR: 0.76; 95%CI 0.22-2.60, p=0.67) and BCG vaccination (relative OR: 1.12; 
95%CI 0.63-2.00, p=0.69). On current evidence it is unclear whether IGRAs 
perform better, worse or the same as the TST because of substantial uncertainty 
in their absolute and relative test performance.
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3.2: Background 
Immunosuppressive therapy after transplantation is necessary to prevent graft 
rejection, but increases risk of bacterial infections, including Mycobacterium 
tuberculosis1. Transplant recipients are up to 74-times more likely to develop 
active tuberculosis (TB) than the general population, and have a substantially 
increased mortality rate (17-40%)1. Due to the non-specific presentation of 
symptoms and atypical pathogenesis of TB in transplant recipients, the diagnosis 
of active TB may be initially missed in up to 33% of cases2. Once diagnosed, 
effective anti-TB drugs are available, but their interactions with 
immunosuppressive agents are complex and may increase or decrease 
immunosuppression levels or give added toxicity1,3,4. It is therefore preferable to 
treat patients before they receive a transplant, and before reactivation of latent 
infection. Anti-TB prophylaxis should be test-directed to ensure that patients at 
most risk of TB receive treatment, whilst avoiding the complications of treatment in 
low risk patients. Current international guidelines recommend that potential 
transplant recipients can be screened with either the tuberculin skin test (TST) or 
an interferon gamma release assay (IGRA), or both1.  
 
The TST measures the immune response of a subject to an intradermal injection 
of purified tuberculin protein. After placement of tuberculin protein, the induration 
of swelling around the injection site is measured 24-48 hours later. Current 
guidelines recommend an induration of 5mm or greater as the cut-off for a positive 
TST in immunosuppressed patients, and 10mm or greater in immunocompetent 
patients. Several attributes of the TST that may affect its accuracy in transplant 
candidates. The tuberculin antigen used in the TST shares immunogenic epitopes 
with the Bacille Calmette Guerin (BCG) vaccination. As a result, BCG vaccinated 
patients may return false positive TST results5. To operate correctly, the TST relies 
on the immunocompetency of the test subject. The presence of no induration after 
48 hours may indicate the absence of latent TB, but it may also indicate 
immunosuppression6.  
 
Interferon-γ release assays are designed to detect the TB-specific cell mediated 
immune response of people previously exposed to TB. IGRAs are available in two 
formats; the enzyme-linked immunosorbent assay (ELISA), which that measures 
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the titre of interferon-γ produced by T cells, and the enzyme-linked immunospot 
assays (ELISPOT), which measures the number of T cells producing interferon-γ. 
IGRAs may be advantageous in the diagnosis of latent TB because they are not 
confounded by BCG vaccination and have a negative mitogen control.  
 
The relative diagnostic accuracy of IGRAs and the TST in transplant candidates is 
unknown and may not be transferable from the end-stage kidney disease setting 
because transplant recipients have reduced cell-mediated immunity. In this 
systematic review we aimed to determine whether ELISA- or ELISPOT based 
IGRAs are more accurate than the TST for diagnosing latent TB in candidates for 
solid organ transplant. 
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3.3: Methods 
Study inclusion/ exclusion criteria 
We included all studies in any language that reported the results of a test for latent 
TB, and at least one risk factor for tuberculosis in solid organ transplant 
candidates or recipients. Studies including cases of active TB were excluded when 
data for active cases could not be separated from the rest of the study population. 
Case studies and case series were also excluded.   
 
Search strategy 
We searched MEDLINE and EMBASE on 1 July 2014 for studies that met our 
inclusion criteria. The search strategy we used was developed in collaboration with 
a medical librarian and combined terms for transplant candidates/ recipients, with 
terms for tests, and terms for TB (see Supplementary Table 1 for detail). Relevant 
studies were also identified through searches of reference lists from key studies 
and systematic reviews, and by correspondence with experts in field. 
 
Data abstraction 
Two authors (TR and KN) independently reviewed search results and extracted 
data from included studies using standardised data extraction forms. Data was 
extracted on study methodology, patient characteristics, test results and risk 
factors for TB. Where additional data was required, corresponding authors were 
contacted by email and requested to provide data. Discrepancies were resolved by 
consensus with a third author (AW).  
 
Quality assessment 
We assessed study quality with an adapted Quality Assessment of Diagnostic 
Accuracy Studies tool (QUADAS-2). (Supplementary Table 2). QUADAS-2 
appraises four domains of potential bias; patient selection, index test conduct, 
reference standard conduct and flow and timing of tests. The domains for 
reference standard bias and applicability were replaced with domains to assess 
the quality of the latent TB risk factor assessment, as this was the comparator in 
our review.   
 
Statistical analysis 
All statistical analyses were performed in STATA 11 and Review Manger 5.2. 
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Where sufficient data was available, we constructed two by two tables to compare 
risk factors and test results. Indeterminate and negative test results were pooled. 
We calculated Odds Ratios (OR) with 95% confidence intervals (CI) for odds of 
positive test in participants with risk factor, against the odds of a positive test in 
participants without the risk factor. If by chance all study participants had the same 
risk factor or the same test result, resulting in a zero cell, we added 0.5 to all cells 
to allow calculation of an OR7. To compare tests, we calculated the Ratio of Odds 
Ratios (RORs) with 95% CI. Variance was assumed to be 0.5 in calculations of 
standard error for RORs, as this method has been shown to generate conservative 
estimates of 95% CI for RORs8. Meta-analysis summary ORs and RORs were 
calculated using a random effects model weighted by inverse variance. Summary 
RORs were calculated for studies that assessed two or more tests in the same 
population which enabled a direct comparison of test performance to be made. 
Chapter 3: Tests for latent tuberculosis in solid organ transplantation: a systematic review and meta-analysis 
 40 
3.4: Results 
Studies identified 
We identified 31 reports of 36 relevant studies from our search of online medical 
databases, and a further 15 studies from previous work and correspondence with 
experts. In total 46 reports of 41 studies were included in the review, but only 24 
reports of 18 studies contained sufficient data for meta-analysis (Figure 3.1). 
Characteristics of included studies that contributed to meta-analysis are shown in 
Table 3.1. Eight studies compared an IGRA with the TST directly and 10 studies 
evaluated only the TST. Eight studies were conducted in kidney transplantation, 6 
in liver transplantation, 2 in lung transplantation and 2 in mixed solid organ 
transplantation. Most studies (13/18, 72%) were conducted in countries with a low 
prevalence of TB (<50 cases/ 100,000 persons) and had more males than females 
(16/18, 89%). Mean age of study participants ranged from 34.2-56.4 years. BCG 
vaccination status was not commonly reported.  
 
Risk of bias assessment was hampered by poor reporting of study methodology. 
The poorest domains for incomplete reporting were patient selection bias (6/18, 
33%), index test bias (16/18, 89%) and risk factor assessment bias (17/18, 94%). 
The risk of bias in flow and timing of study was generally considered low (11/18, 
61%), as was the applicability of the patient population (13/18, 72%), index tests 
(16/18, 89%) and risk factor assessment (18/18, 100%) to the review question. A 
high risk of bias was observed in the method of patient selection in 4/18 (22%) of 
studies. We also observed a high risk of bias in the conduct of the index tests in 
2/18 (11%) of studies, flow and timing in (3/18, 17%) of studies, and applicability of 
the patient population in (5/18, 28%) of studies. Refer to Table 3.2 for a summary 
of the risk of bias of included studies. 
 
Association between a positive test result and risk factor 
Similar magnitudes of association between test positivity and risk factors were 
observed across ELISA- and ELISPOT IGRAs, and the TST (see Figure 3.2-3.3). 
For both the IGRAs and the TST, patients were more likely to return a positive test 
if they had a study-defined clinical risk factor for TB (TST: OR 3.87; 95%CI 1.99-
7.56, p<0.01, IGRA: OR 2.56; 95%CI 1.24-5.27, p=0.01), or a radiological 
evidence of past TB (TST: OR 3.18; 95%CI 1.76-5.76, p<0.01, IGRA: OR 2.56; 
95%CI 1.69-3.88, p<0.01). A positive TST result was also associated with patients 
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who had a history of contact with active TB (OR 3.24; 95%CI 1.13-9.29, p=0.03). A 
positive IGRA more likely to occur in participants who had received TB treatment 
(OR 22.31; 95%CI 7.80-63.76, p<0.01), but less likely in immunosuppressed 
patients (OR 0.45; 95%CI 0.27-0.74, p<0.01).  
 
Only two studies assessed the ELISPOT-based IGRA test for detecting latent TB 
in transplant candidates. These studies did not provide sufficient data to determine 
the direction of association with risk factors (see Supplementary figure 3.1). 
Removing only ELISPOT-based IGRA data from our analysis of IGRAs did not 
change the direction of association of positive tests with risk factors, but did widen 
confidence intervals (see Supplementary figure 3.2).  
 
We also identified two studies that assessed the performance of the TST with an 
antigen control panel in potential lung transplant recipients, but insufficient data 
was available to determine the direction of association with risk factors. 
Our subgroup analyses did not identify any significant differences in the 
association of TST positivity with risk factors between studies that assessed 
kidney, liver, or mixed populations of transplant candidates (clinical risk factors, 
Chi2=0.02, p=0.89; radiological evidence of past TB, Chi2=0.03, p=0.87; contact 
history, Chi2=2.05, p=0.36; previous TB, Chi2=0.00, p=0.96; BCG, Chi2=3.37, 
p=0.06). Similarly, no difference in odds of IGRA positivity was found between 
kidney, liver or mixed transplant candidates (clinical risk factors, Chi2=0.55, 
p=0.46; radiological evidence of past TB, Chi2=0.34, p=0.56; contact history, 
Chi2=0.83, p=0.36; previous TB, Chi2=0.00, p=0.96; diabetes, Chi2=2.34, p=0.31; 
BCG, Chi2=1.20, p=0.55).  
 
Interferon gamma release assays versus Tuberculin skin test  
Data available for head-to-head comparison of tests was sparse. Five studies 
compared an IGRA with the TST, including three studies of ELISA-based IGRA 
and two studies of ELISPOT-based IGRAs, see Figure 3.4. We found no evidence 
of a difference in odds of a positive test between IGRAs and the TST for transplant 
candidates with clinical risk factors (ROR 0.65; 95%CI 0.36-1.18, p=0.15), 
radiological evidence of past TB (ROR 1.09; 95%CI CI 0.22-5.35, p=0.92), history 
of contact with active TB (ROR 1.75; 95%CI 0.15-20.01, p=0.65), diabetes (ROR 
0.76; 95%CI CI 0.22-2.60; p=0.67) or BCG vaccination (ROR 1.12; 95%CI 0.63-
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2.00, p=0.69). One study found that people a previous TB infection were more 
likely to test positive with an ELISA-based IGRA than the TST (ROR 22.15 (95%CI 
1.05-466.73, p=0.05). 
 
Our sensitivity analysis (see Supplementary figures 3.3-3.4) found that ELISPOT-
based IGRAs were more likely to return a positive result than the TST in diabetic 
transplant recipients (ROR 0.45; 95% CI 0.21-0.97, p=0.04). No data was 
available to compare the relative performance of ELISA- and ELISPOT-based 
IGRAs. 
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3.5: Discussion 
This is the first systematic review to examine the performance of tests for latent TB 
in solid organ transplant recipients and candidates. The absence of a reference 
standard test precludes the generation of sensitivity and specificity and precision 
as metrics of relative diagnostic performance. In this review we synthesized data 
from 18 studies that assessed diagnostic accuracy by comparing test results 
against risk factors as proxy reference standards. We found that positive TST and 
IGRA test results were closely associated with risk factors for tuberculosis. People 
who had clinical risk factors for tuberculosis, radiological evidence of past TB, or 
had contact with active TB were 3-4 times more likely to return a positive TST 
result. Similarly, people who had clinical risk factors for tuberculosis or radiological 
evidence of past TB were three times more likely to return a positive IGRA. We 
also found that people with a history of previous TB were 22 times more likely to 
have a positive IGRA result.  
 
To determine whether IGRAs perform better, worse or the same as the TST, we 
also examined the relative association of tests with risk factors in studies that 
reported the results of at least two of these tests, head-to-head. We found no 
significant difference in the odds of testing positive in the presence of risk factors 
between the TST and IGRAs, except in people who had previous TB, where IGRA 
was better. A person previously treated for TB was found to be 22 times more 
likely to return a positive IGRA than a positive TST, however confidence intervals 
were wide. No data were available to compare the performance of ELISA- and 
ELISPOT-based IGRAs. Given these data, it remains uncertain whether IGRAs or 
the TST are superior for detecting latent tuberculosis in people undergoing solid 
organ transplant. Clinically important differences may exist but data are too sparse 
to be confident about the true relative test performance of TST and IGRA for latent 
TB. 
 
Our results are consistent with our earlier findings about these tests for latent 
tuberculosis in people with end-stage kidney disease9. Like transplant recipients, 
people with end-stage kidney disease were also more likely to have a positive 
ELISA-based IGRA if they had radiological evidence of past TB or had contact 
with actives cases of TB. While this review was unable to show any difference in 
test performance between IGRAs and the TST, in the end-stage kidney disease 
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population a positive ELISA-based IGRA was four times more likely in people with 
radiological evidence of past TB than a positive TST, and three times more likely 
in people who had a contact history with TB. Another systematic review in the 
general population, also found that IGRAs were approximately four times more 
likely to return a positive result than the TST in people who had high TB 
exposure8. 
 
Current international guidelines for screening solid organ transplant candidates for 
latent TB do not make specific recommendations about which test should be 
used1, concluding that either test may be used, singly or in combination. 
Additionally, no guidance is offered on which modality of IGRA, ELISA- or 
ELISPOT-based, should be used. Our review shows there are currently insufficient 
data to differentiate one IGRA from another, and so current guidelines are still 
appropriate for the transplant setting. A recent systematic review of TB screening 
strategies found that IGRA plus TST screening, and IGRA screening alone were 
the most cost-effective strategies in high risk groups.10 In resource poor settings, 
clinicians may wish to consider using IGRAs over the TST as they are cheaper, 
and only require a single patient visit to collect blood, while the TST requires two 
clinical visits.  
 
An ideal reference standard is able to perfectly discriminate between the presence 
and absence of disease, but risk factors often correlate imperfectly with disease 
status. For this reason, indicators of test accuracy generated by the comparison of 
tests with proxy reference standards may not reflect true test performance. This 
may be an inevitable limitation of this review, given a reference standard is not 
available. Previous reviews on latent TB tests have used studies in different 
populations, composed of either patients with active TB or healthy individuals to 
estimate test sensitivity and specificity respectively11-13. Reviews based on these 
studies have limited applicability because the host immune response to active TB 
infection is different to latent TB and healthy individuals are immunocompetent14,15. 
 
In summary, we found there is no evidence of a difference in test performance 
between IGRAs and the TST in people undergoing solid organ transplantation, 
except in patients who had previous TB, when IGRA was superior. We also found 
no data on the relative test performance of ELISA- and ELISPOT-based IGRAs. At 
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this time no specific recommendations on test usage are appropriate. Future 
studies should aim to assess the relative diagnostic performance of IGRAs and 
TST using well-designed large trials with risk factors for TB as proxy references 
standards. Additionally, a randomized controlled trial of test-directed treatment 
may also elucidate whether any difference in diagnostic performance between 
IGRAs and TST is associated with improved clinical outcomes for patients
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Figure 3.1: Identification of studies included in review 
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Figure 3.2: Odds of positive TST in transplant candidates with risk factors for TB 
 
*Clinical risk factors as defined by study, IV, Random: inverse variance, random 
effects meta-regression, 95% CI: 95% confidence interval 
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Figure 3.3: Odds of positive IGRA in transplant candidates with risk factors for TB 
 
*Clinical risk factors as defined by study, IV, Random: inverse variance, random 
effects meta-regression, 95% CI: 95% confidence interval 
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Figure 3.4: Relative performance of the TST and IGRAs 
*Clinical risk factors as defined by study, IV, Random: inverse variance, random 
effects meta-regression, 95% CI: 95% confidence interval 
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Table 3.1: Characteristics of included studies  
Study Comparison N Country Male (n, %) Age (mean ± SD*) 
Prevalence of TB 
(cases/105 [95% 
CI])§†  
       
Kidney transplant       
Agarwal 201016 TST 200 India 169 (84.5) 34.7 ± 11.1 438 (382-498) 
Aydogan 200917 TST 50 Turkey 24 (48.0) 34.2 ± 12.7 25 (12-43)‡   
Basolgu 200618 TST 7 Turkey nr§ nr 28 (13-48)‡   
Merino 201019 TST 992 Brazil 575 (58.0) 42 61 (26-112)  
Shankar 200520 TSTa 108 India 78 (72.2) 37.8 ± 11.8 365 (295-443)‡   
Ahmadinejad 201321 TST vs QFT 187 Iran 38 (59.4) 38.5 ± 12.1 29 (11-55) 
Kim 201322 TST vs QFT 109 South Korea 68 (62.4) 44.7 ± 11.5 431 (156-842) 
Kim 201123,24 TST vs TSPOT 312 South Korea 176 (56.4) 42.5 ± 10.2 431 (156-842) 
Liver transplant       
Benito 200225 TST 529 Spain 333 (62.9) 50 (12-66)||  30 (12-55) 
Fabrega 201226 TST 145 Spain 111 (76.6) 54 (20-66)||  27 (11-50) 
Singh 200227 TST 36 Germany 36 (100.0) nr 27 (10-50) 
Casas 201128 TST vs QFT 110 Spain 72 (65.5) 56.4 ± 7.6 20 (8.2-37) 
Manuel 200729 TST vs QFT 153 USA 122 (79.7) 54.6 ± 8.2 6.4 (2.6-12) 
Lindemann 200930 TST vs TSPOT vs LTT 48 Germany 21 (43.8) 54 (22-69)||  9.4 (3.7-18) 
Lung transplant       
Caruso 201231 TSTa 100 USA 56 (56.0) 56.1 5.1 (2.1-9.4) 
Roman 200032 TSTa 61 Spain 38 (62.3) 42 (16-67)||  30 (12-55) 
Mixed solid organ transplant      
Povitz 201033 TST vs QFT 43 Canada nr nr 6.7 (2.7-13) 
Theodoropoulos 201234 TST vs QFT 2394 USA 564 (59.9) 54.2 ± 11.4 5.3 (2.2-9.9) 
 
*Standard Deviation, † WHO data for first year of study, ‡ Data for year of publication, § Not reported, || Median (range)  
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Table 3.2: Risk of bias of included studies 
 
 BIAS APPLICABILITY  
STUDY PATIENT 
SELECTION 
INDEX 
TEST(S) 
RISK 
FACTORS 
FLOW AND 
TIMING 
PATIENT 
SELECTION 
INDEX 
TEST(S) 
RISK 
FACTORS 
KIDNEY        
Agarwal 201016  ? ?     
Ahmadinejad 201321  ? ?     
Aydogan 200917 ? ? ?     
Basoglu 200618 ? ? ?     
Kim 201123,24  ? ?     
Kim 201322  ? ?     
Merino 201019 ? ? ?   ?  
Shankar 200520  ? ?     
LIVER        
Benito 200225  ? ? ?    
Casas 201128  ? ?     
Fabrega 201226  ? ?     
Lindemann 200930 ? ? ?     
Manuel 200729  ?      
Singh 200227  ? ?     
LUNG        
Caruso 201231 ? ? ? ?  ?  
Roman 200032 ? ? ?     
MIXED        
Povitz 201033   ? ?    
Theodoropoulos 201234   ? ?    
 
 Low risk of bias,  High risk of bias,? Unclear risk of bias
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Supplementary figure 3.1: Odds of positive ELISA-based IGRA in transplant 
candidates with risk factors for TB 
 
 
 
 
*Clinical risk factors as defined by study, IV, Random: inverse variance, random 
effects meta-regression, 95% CI: 95% confidence interval 
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Supplementary figure 3.2: Odds of positive ELISPOT-based IGRA in transplant 
candidates with risk factors for TB 
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Supplementary figure 3.3: Relative performance of the TST and ELISA-based 
IGRA test 
 
 
*Clinical risk factors as defined by study, IV, Random: inverse variance, random 
effects meta-regression, 95% CI: 95% confidence interval 
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Supplementary figure 3.4: Relative performance of the TST and ELISPOT-based 
IGRA test 
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4.1: Abstract 
Active tuberculosis (TB) is a dangerous complication of kidney transplantation. 
International guidelines recommend pre-transplant screening for latent TB, but 
little is known about the frequency of testing, or prevalence of risk factors among 
potential transplant recipients in Australia. We conducted a cross-sectional study 
of all patients who underwent kidney transplant assessment from 2011-2012 in a 
regional transplant centre in Australia. We assessed the prevalence of risk factors, 
as well as the frequency of testing, and the frequency of positive test results when 
tested. We collected data on patient characteristics, risk factors for TB, and tests 
from hospital records. Two-hundred and one patients underwent kidney transplant 
assessment over the 2 year study period. Patients had a mean age of 50.8 ± 12.6  
years, 63.7% were male and 22.9% had been BCG vaccinated. The most frequent 
cause of kidney failure was diabetic nephropathy (29.4%). At least one risk factor 
for latent TB, other than chronic kidney disease, was present in 49.8% of patients. 
The most prevalent risk factors for latent TB were high-risk country of birth 
(29.4%), diabetes mellitus (27.4%), and prior immunosuppression (20.9%). Forty 
seven patients (23.4%) were tested for latent TB. Of patients with at least one risk 
factor for latent TB, only 37.0% were tested. Thirteen (35.1%) of the 37 people 
with risk factors for TB and were tested, returned a positive result. Despite a high 
prevalence of risk factors for TB in candidates for kidney transplantation, latent 
infection may be missed in transplant work-up due to under use of available tests. 
Chapter 4: Mismatch between risk of tuberculosis and testing practices in people being assessed 
kidney transplantation 
 63 
4.2: Background 
Active tuberculosis (TB) is a dangerous complication of kidney transplantation with 
a high mortality rate (17-40%)1. For the majority of transplant patients, active TB 
infection occurs from the reactivation of a latent infection acquired many years 
earlier. In Australia, candidates for kidney transplantation who are receiving 
dialysis are 10 times more likely to develop active TB than their general population 
counter parts2. After receiving a transplant, the risk of developing active TB 
increases further because of immunosuppression induced by anti-rejection drugs3. 
Chemoprophylaxis before transplant is effective in preventing active TB, but is also 
known to cause hepatoxicity, neurotoxicity and unpredictable drug-drug 
interactions with immunosuppressant therapy4-7. Using risk factor assessment and  
tests for latent TB, chemoprophylaxis can be targeted to transplant candidates at 
most risk of developing active disease, while sparing candidates at low risk from 
unnecessary complications of treatment3,8. 
 
In the absence of a gold-standard test for latent TB, clinical risk factors are a 
useful way of estimating the likelihood of TB infection and can be used in 
conjunction with test information to guide treatment. A recent review found that 
people with end-stage kidney disease who had clinical risk factors for latent TB 
were more likely to return positive interferon gamma release assays (IGRAs) and 
tuberculin skin tests (TST) than people without risk factors9. Specifically, patients 
were more likely to have a positive IGRA if they had radiological evidence of past 
TB or previous contact with active TB cases TB. Identifying groups of patients with 
risk factors for latent TB that are not identified under current routine clinical 
practices may decrease the morbidity and mortality associated with tuberculosis in 
kidney transplantation.  
 
Current international guidelines recommend all transplant recipients are screened 
with the tuberculin skin test (TST) and/or an interferon gamma release assay 
(IGRA) prior to transplant1. In Australia, the actual frequency of pre-transplant 
screening, the types of tests used and the characteristics of patients who receive 
screening is unknown. With this study, we aimed to describe the risk profile of 
latent TB in patients undergoing kidney transplant assessment and the testing 
practices used by clinicians to investigate this disease.  
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4.3 Methods 
Patient population 
Ethics approval to conduct this study was granted by Western Sydney Local 
Health District Human Research Committee (LNR/13/WMEAD/120). We 
retrospectively enrolled all patients who attended our transplant clinic between 
January 2011 and December 2012. Our transplant clinic is a major regional centre 
for kidney transplant in Australia. Patients on our active transplant waiting list 
return to the clinic every two years for review. A two-year sample was chosen to 
capture all patients currently active on the waiting list as well as new patients 
undergoing transplant assessment for the first time.  
 
Medical records search 
Two investigators searched electronic and paper hospital records for relevant 
data. We collected data on patient characteristics, including age, sex, aetiology of 
renal disease, time on dialysis and number of previous transplants. We also 
collected data on risk and protective factors for latent TB, including HIV status, 
country of birth, diabetes, malignancy, previous TB disease, radiological evidence 
of TB, contact with active TB, previous treatment with immunosuppression, 
smoking and BCG vaccination. Refer to Supplementary Table 4.1 for definitions of 
risk factors. Additionally, we recorded the results of tests for latent TB, including 
the tuberculin skin test, interferon gamma release assays and chest X-ray. 
Patients were not asked to complete any tasks or provide additional information. A 
full list of extracted data is available in Supplementary Table 4.2. 
 
Statistical analysis 
All statistical analyses were conducted in STATA 11.0 (Texas, USA). We 
calculated the prevalence of risk factors and frequency of testing for latent TB as 
simple proportions. All continuous variables are reported with mean, standard 
deviation and range.  
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4.4: Results 
Population characteristics 
Two hundred and forty-two participants were enrolled in the study, but complete 
records were only available for 201 patients. Characteristics of the study 
participants are summarised in Table 4.1. Study participants were mostly male 
(128, 63.7%), had mean age of 50.5 ± 12.6 years (range 21.0-73.2) and had been 
on dialysis for a mean of 3.9 ± 3.0 years. Candidates who had at least one prior 
kidney transplant accounted for 13.9% of the total study population. Less than half 
of all participants smoked (91, 45.3%) and approximately one quarter (46, 22.9%) 
were BCG vaccinated. The most common aetiology of end stage kidney disease 
was diabetic nephropathy (59, 29.4%), followed by IgA nephropathy (33, 16.4%) 
and polycystic kidney disease (19, 9.5%). 
 
Prevalence of risk factors for tuberculosis 
We observed a high prevalence of risk factors for latent TB in the study group (see 
Table 4.2). Overall, 101 (49.8%) of participants had at least one risk factor for 
latent TB. Of the 101 patients with risk factors for TB, 68 (67.3%) had one risk 
factor, 22 (21.7%) and two risk factors, and 10 (10.9%) had three or more risk 
factors in combination. The most common risk factors for latent TB were a high-
risk country of birth 59 (29.4%), insulin-dependent diabetes mellitus (55, 27.4%) 
and previous immunosuppressive drug use (42, 20.9%). We also identified 16 
patients who had a history of cancer, 12 patients with radiological evidence of past 
TB, nine patients who had been treated for TB in the past, and six patients who 
had a history of contact with active cases of TB. In two patients who were 
previously transplanted, the donors had a history of TB. One patient had 
occupational exposure to TB.  
 
Frequency of testing 
Forty-seven patients (23.4%) were tested for latent TB. Forty patients were tested 
using an interferon-gamma release assay (QuantiFERON Gold In-Tube), seven 
patients had a TST, and three patients had both an IGRA and a TST. Of the 47 
patients tested, 14 were positive for latent TB, 26 were negative, and for seven 
patients the test was either indeterminate, ordered but never completed, or the test 
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result was not recorded. There was no disagreement between the IGRA and TST 
in patients that received both tests.  
 
Of the 100 candidates with at least one risk factor for TB, only 36 (36%) were 
tested for latent TB. The frequency of testing across risk factors was inconsistent. 
Despite being the most common risk factor for TB, people who were from a high-
risk country of birth, had diabetes, or been taking immunosuppressive drugs were 
the least likely to be tested (see Table 4.2). The highest rates of testing were 
observed in people with a history of TB treatment (100%), people who had contact 
with cases of active TB (83%) and people with radiological evidence of past TB 
(75%).  
 
Frequency of positive tests 
Positive test results were more common in kidney transplant candidates with risk 
factors for TB. Of the 14 positive test results, 13 occurred in candidates with one 
or more risk factors. We observed a trend of increasing likelihood of test positivity 
with increasing number of risk factors (see Figure 4.1).  Of the 37 participants who 
both received a test for latent TB and had at least one risk factor for TB, 13 
(36.1%) tested positive. The highest rate of test positivity were observed in 
participants with a history of TB treatment (77.8%), see Table 4.2. 
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4.5: Discussion 
Despite a high prevalence of risk factors for TB amongst kidney transplant 
candidates, we observed a low frequency of testing for latent TB in this transplant 
centre. A recent Australian linking transplant and mandatory TB reporting 
databases identified 37 cases of active TB in 14,506 dialysis patients between 
2001 and 2006, corresponding to an incidence of 66.8 cases per 100,000 
persons2. This rate was over 10 times higher than the general Australian 
population, and mortality was also higher. Given that only a small fraction (5-10%) 
of people with latent TB go on to develop active TB, this data suggests a 
significant reservoir of latent TB may exist in candidates for kidney transplant in 
Australia. Current international guidelines recommend that all transplant recipients 
should be screened for latent TB, and preferably prior to transplant. At our centre 
however, only 23.4% of all candidates for transplant were tested, and only 37% of 
candidates with risk factors for TB were tested. The low frequency of testing for 
latent TB we observed at this centre highlights missed opportunities for 
interventions and prevention of active disease, and an unawareness of 
international guidelines among staff.   
 
Interestingly, the likelihood of testing varied across risk factors for TB. All patients 
with a history of prior TB underwent testing, but only 52.5% of candidates with a 
high-risk country of birth were tested. This suggests that some clinicians may not 
recognise certain risk factors for TB as readily as others, or place different 
magnitudes of importance on risk factors in their decision to order a test. Clinicians 
were also more likely to order a test when a patient presented with two or more 
risk factors for TB, indicating that a clinicians’ decision to test was influenced by 
not only the type of risk factors, but also how many occurred in combination. 
Evaluating the risk of TB in potential transplant recipients is a complex task. 
Clinicians may benefit from a diagnostic algorithm for combining risk factor 
information into a finite measure of risk.  
 
Whilst not always practical, pre-transplant screening and treatment is 
advantageous as the risk of TB reactivation increases after transplant and 
symptoms of active TB can often be nonspecific and difficult diagnose. This study 
found a high rate of test positivity amongst patients with who had prior TB therapy 
(80%), indicating that tests for latent TB could be useful tools for identifying 
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individuals at high risk of TB. This finding is congruent with a recent systematic 
review of tests for latent TB in people with end stage kidney disease, which found 
that patients with a medical history of TB were six times more likely to test positive 
on an interferon gamma release assay and two times more likely to test positive 
on a tuberculin skin test9.  
 
While the generalisability of our results are limited by our small sample size and 
single centre setting, the data presented here reflect the experiences of a large 
kidney transplant centre and may indicate a larger problem in TB management 
across other transplant centres in Australia. This study highlights the need for 
nation-wide evidence-based TB screening protocols, as well as programs for 
education and training in the management of TB. We recommend that all kidney 
transplant clinics evaluate their current TB screening practices and where 
necessary incorporate current international guidelines on latent TB screening into 
their pre-transplant assessment protocols.  
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Figure 4.1: Likelihood of positive latent TB test increases with number of risk 
factors 
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Table 4.1: Characteristics of kidney transplant candidates 
Characteristic N (%) 
Total  201 (100.0) 
Males 128 (63.7) 
Age (mean ± SD, years) 50.5 ± 12.6 
≤ 30 15 (7.5) 
31-40 35 (17.4) 
41-50 39 (19.4) 
51-60 53 (26.7) 
≥ 61 59 (29.4) 
BCG vaccinated 46 (22.9) 
BMI (mean ± SD) 27.8 ± 5.1   
Ever smoked 91 (45.3) 
Diabetes mellitus 68 (33.8) 
Insulin dependent 55 (27.4) 
Non-insulin dependent 13 (6.5) 
Prior kidney transplant 28 (13.9) 
Time on dialysis (mean ± SD, years) 3.9 ± 3.0 
Infectious diseases  
Human immunodeficiency virus 0 (0.0) 
Hepatitis B (Chronic)* 1 (<1.0) 
Hepatitis C†  3 (1.0) 
Aetiology of ESKD  
Diabetic nephropathy  59 (29.4) 
IgA nephropathy  33 (16.4) 
Polycystic kidney disease  19 (9.5) 
Focal segmental glomerulosclerosis 15 (7.5) 
Reflux nephropathy 9 (4.5) 
Other‡ 49 (24.4) 
Unknown 17 (8.5) 
* HBV surface Ag detected, HBV core Ab reactive 
†HCV antibody reactive, HCV RNA detected 
‡Posterior urethral valves disease, trauma, amyloidosis, urosepsis, congenital defects, 
hypertension, glomerulonephritis, medullary cystic disease, drug-induced nephropathy, 
membranous glomerulonephritis, Wegener’s granulomatosis, obstructive uropathy  
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Table 4.2: Prevalence of risk factors for TB in kidney transplant candidates 
 
Number of risk factors N (%) 
Total = 201 
Tested (%) 
Total = 47 
Test positive (%) 
Total = 14 
0 101 (50.2) 10 (21.3) 1 (7.1) 
1 68 (33.8)   15 (32.0) 2 (14.3) 
2 22 (10.9) 13 (27.6) 5 (35.7) 
≥3 10 (5.0) 9 (19.1) 6 (42.9) 
Risk factors history    
Any risk factor 100 (49.8) 37 (78.7) 13 (93.0) 
High risk country of birth 59 (29.4) 31 (66.0) 13 (93.0) 
Insulin dependent diabetes 55 (27.4) 13 (27.6) 2 (14.3) 
Immunosuppressive drugs 42 (20.9) 13 (27.6) 5 (35.7) 
Malignancy 16 (8.0) 4 (8.5) 2 (14.3) 
Old TB on CXR 12 (6.0)  8 (17.0) 4 (28.6) 
Prior TB therapy 9 (4.5) 9 (19.1) 7 (50.0) 
Contact history 6 (3.0) 5 (10.6) 2 (14.3) 
Other*  4 (2.0) 3 (6.4) 1 (7.1) 
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Supplementary table 4.1: Definitions of risk factors for latent tuberculosis 
Risk factor Definition 
High risk country of birth A participant born in a country with 50 or more 
cases of tuberculosis per 100,000 persons per 
year. Prevalence of tuberculosis was estimated 
from World Health Organisation data. 
Contact history A participant or clinician report of contact with an 
individual with confirmed or suspected active 
tuberculosis.  
Radiological evidence of past 
tuberculosis 
Radiological evidence of old tuberculosis on chest 
x-ray or computed tomography scan, including 
pulmonary nodules in the hilar or upper lobes of 
the lung, pleural scarring or volume loss.  
Prior anti-tuberculosis therapy A participant or clinician report of prior anti-
tuberculosis therapy, including ethambutol, 
isoniazid, rifampicin or pyrazinamide, or a 
combination thereof. 
Diabetes mellitus A participant with either insulin or non-insulin 
dependent diabetes mellitus. We excluded 
participants with gestational diabetes mellitus. 
Prior immunosuppression 
therapy 
A participant who had previously received any 
immunosuppressive therapy prior to 
transplantation, including glucocorticoids, 
cytostatics, antibodies, immunophilins 
(ciclosporin, tacrolimus, sirolimus), interferons, 
tumour necrosis factor binding agents and 
mycophenolate.  
Malignancy A participant with a history of any malignant 
cancer except basal and squamous cell 
carcinomas. 
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Supplementary table 4.2: Summary of data extracted from patient records 
 
Variable Data collected 
Patient characteristics  
Date of last transplant review Day/ month/ year 
Transplant type Deceased donor/ living related donor/ 
living unrelated 
Suitability for transplant  Yes/ no/ marginal 
Etiology of renal failure Disease 
Age Years 
Sex Male/ female 
Height  Meters 
Weight  Kilograms 
Dialysis and kidney transplant history  
Time on dialysis Months 
Number of previous kidney transplants 1/ 2/ ≥3 
Type of previous transplant  Deceased donor/ living related donor/ 
living unrelated 
Time since previous transplant Months 
Time since previous transplant failure Months 
Risk factors for tuberculosis  
Diabetes  Non diabetic, insulin dependent 
diabetic, non-insulin dependent diabetic 
Smoking Current, previous, never 
Human immunodeficiency virus  Positive/ negative 
Hepatitis C Positive/ negative 
Hepatitis B profile Surface antigen/ surface antibody/ core 
antibody/ e-antigen/ e-antibody) 
Cancer profile  Type of malignancy/ time since last 
malignancy 
Country of birth Country, prevalence of tuberculosis 
Bacillus Calmette-Guerin vaccination Vaccinated/ non vaccinated 
Tuberculosis treatment history Time since treatment/ drugs prescribed 
Tuberculosis contact history  Time since last tuberculosis contact/ 
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proximity/ time 
Prior immunosuppressant therapy Yes/ no/ drugs used 
Tests for tuberculosis  
Tuberculin Skin Test (date, result) Date/ result 
QuantiFERON (date, result) Date/ result 
TSPOT.TB (date, result) Date/ result 
Chest X-ray (date, result) Date/ result 
Chest computed tomography scan (date, 
result) 
Date/ result 
Sputum culture (date, result) Date/ result 
Mycobacterium nucleic acid test (date, 
result) 
Date/ result 
Ziehl-Neelsen stain (date, result) Date/ result 
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The cross-sectional analytic study presented in Chapter 2 examined the 
performance of fourteen methodological filters for diagnostic studies. We found 
that while methodological filters generally lacked the sensitivity for systematic 
review purposes, some filters could be useful in clinical setting to reduce the 
volume of search results. The surprise finding of this study was that the current 
‘specific’ clinical queries limit for diagnosis (used in PubMed and Ovid SP) missed 
up to 80% of studies in nephrology journals. Other filters (Deville 2000 Broad, 
Deville 2000 Balanced, Haynes 2004 Balanced, and Vincent 2003 Narrow) had 
similar specificity to the ‘specific’ clinical queries limit, but identified a greater 
proportion of the total evidence. When systematic reviews are not available, 
clinicians need fast access to primary studies from the literature. Our findings in 
Chapter 2 will help clinicians in the kidney transplant specialty to access 
information about diagnostic tests more efficiently, improving their utilisation of 
evidence-based medicine, and ultimately improving outcomes for patients. A 
limitation of this study was the imprecision around our estimates of filter sensitivity, 
which arose because of the low prevalence of diagnostic test accuracy studies in 
the literature. In the future we plan to extend this study to additional nephrology 
and transplant journals, as this will allow us to both validate our findings, and 
derive more precise estimates of filter sensitivity. Additionally, we also wish to 
extend this research to assess the quality of diagnostic studies identified by filters. 
In Chapter 3 we presented the results of a systematic review of test for latent 
tuberculosis in the solid organ transplant setting. The primary challenge of this 
review was to use novel methodologies for the meta-analysis of data from studies 
of tests with no reference standards. The conventional approach to the 
assessment of diagnostic test accuracy is to compare the results of a new test 
against a reference standard, and to use this data to derive estimates of test 
sensitivity, specificity and precision. For latent TB however, there is no reference 
standard test, and therefore standard methodologies fail.  
In our earlier work on a systematic review of tests for latent TB in people with end-
stage kidney disease, we identified studies in the literature that reported the 
results of tests for latent TB stratified by risk factors for TB. We were able to use 
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this data to generate estimates of test performance, as the odds of a positive test 
in the presence of clinical risk factors for TB, and conduct a meta-analysis.  
Applying these same methods to the solid organ transplant population, the 
systematic review presented in Chapter 3 found that people undergoing solid 
organ transplant, were more likely to have a positive interferon gamma release 
assays (IGRAs) and tuberculin skin tests (TST) if they had radiological evidence of 
past TB, a history of contact with past TB, or previous TB treatment. Interestingly, 
when we compared our results to our earlier work in people with end-stage kidney 
disease, we found that the odds of test positivity with risk factors were very similar 
in magnitude. Contrary to our original hypothesis, this suggests IGRAs and the 
TST may perform similarly in both the solid organ transplantation and end stage 
kidney disease populations.  
Another finding of our systematic review was little evidence exists on the relative 
performance of IGRAs and the TST. Current available data was inadequate to 
determine whether IGRAs perform better, worse or the same as the TST. The 
current international guidelines for screening solid organ transplant recipients for 
latent TB recommend using either the TST or IGRA, or both in combination. Our 
findings support these guidelines and until new evidence emerges, no further 
clinical recommendations can be made. To address this uncertainty, we are 
planning a large study that will compare the performance of IGRAs and the TST 
against a comprehensive risk factor assessment in people undergoing kidney 
transplantation. This study will be conducted across two major centres for 
transplant in Australia and will include both ELISA- and ELISPOT-based IGRAs.  
Another future line of investigation will be to determine whether the testing for 
latent TB actually improves outcomes for people undergoing transplant. It is 
unclear at present whether cases of latent TB identified by tests would have ever 
progressed to active TB without prophylactic treatment. A randomised controlled 
trial of test-directed treatment would be of value for assessing the overall impact of 
testing programs on patient outcomes.  
The cross-sectional descriptive study presented in Chapter 4 was conducted to 
evaluate the risk of latent tuberculosis in the Australia transplant setting, and to 
assess the adequacy of current screening practices. We searched the hospital 
records of 201 candidates for kidney transplant at our centre and found that 
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approximately half of all patients had at least one risk factor for latent TB. The 
most common risk factors for latent TB were a high-risk country of birth, diabetes 
and prior immunosuppression therapy. Surprisingly, despite the high prevalence of 
risk factors, less than a quarter of candidates were screened for latent TB before 
transplant. More concerning, was that only 36% of the 101 patient with risk factors 
for TB were tested. We also found that clinicians were more likely to order a test 
for latent TB when candidates had two or more risk factors for TB in combination, 
and when candidates had a history of contact with active TB or prior 
chemoprophylaxis. This study demonstrates that that candidates for kidney 
transplant are at increased risk of tuberculosis and highlights the need for a 
nation-wide TB screening protocol in work-up for transplant.  
The ultimate aim of this body of work was to (1) improve the availability of 
diagnostic evidence to clinicians, (2) provide an unbiased synthesis of the 
evidence on tests for latent TB in transplantation, and (3) to increase our 
understanding of the risk latent tuberculosis in the Australian transplant setting. 
Our findings will enable clinicians to search MEDLINE quickly and efficiently for 
diagnostic accuracy studies, make evidence based decisions about the results of 
tests for latent TB, and have a greater understanding of the epidemiology of latent 
TB in candidates for kidney transplant. Combined, we hope that this information 
can be used to reduce the morbidity and mortality associated with TB in 
transplantation. 
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APPENDIX 1: TESTS FOR LATENT TUBERCULOSIS IN 
PEOPLE WITH END STAGE KIDNEY DISEASE: A 
SYSTEMATIC REVIEW AND META-ANALYSIS 
 
Original Investigation
Tests for Latent Tuberculosis in People With ESRD: A
Systematic Review
Thomas E. Rogerson, BSc,1,2 Sharon Chen, MBBS, PhD,3 Jen Kok, MBBS,3
Andrew Hayen, BA, MM(Biostat), PhD,2 Jonathan C. Craig, MBBS, PhD,1,2
Kamal Sud, MBBS,3 Kathy Kable, BASci, MN,3 and
Angela C. Webster, MBBS, MM(Clin Epid), PhD1,2,3
Background: The relative diagnostic accuracy of interferon  release assays (IGRAs; based on ELISA
[enzyme-linked immunosorbent assay] or ELISPOT [enzyme-linked immunosorbent spot], ie, the QuantiFERON and
T-SPOT.TB tests, respectively) and the tuberculin skin test (TST) for latent tuberculosis (TB) infection in
people with end-stage kidney disease is uncertain and national guidelines for their use are inconsistent.
Study Design: Systematic review.
Selection Criteria for Studies: Evaluated performance of tests for latent TB with clinical risk-factor
assessment.
Setting & Population: People with end-stage kidney disease (chronic kidney disease stage 5 [eGFR 15]
or kidney transplant recipients). No limits on setting.
Index Tests: ELISA- or ELISPOT-based IGRAs, TST, assays to detect antimycobacterial antibodies, and
flow cytometry–based tests.
Outcomes: Odds of test positivity with clinical risk factor for latent TB, expressed as ORs and relative ORs
(RORs).
Results: 47 studies (6,828 participants) were included, but only 30 studies (4,546 participants) contained
sufficient data to contribute to meta-analysis. Studies were predominately in the dialysis population (23/30;
3,700 participants) in countries with low to moderate TB prevalence (0.0-50.0 cases/105 persons). BCG
vaccination rate was variable (2.7%-100.0%). 9 studies compared IGRAs with the TST directly, 17 studies
evaluated the TST only, and the other 4 studies evaluated other tests. Compared to a positive TST result, a
positive ELISA-based IGRA result was associated more strongly with radiologic evidence of past TB (ROR,
4.29; 95% CI, 1.83-10.3; P  0.001) and contact with active TB (ROR, 3.36; 95% CI, 1.61-7.01; P  0.001).
Compared to a negative TST result, a negative ELISA-based IGRA result was associated more strongly with
BCG vaccination (ROR, 0.30; 95% CI, 0.14-0.63; P  0.002). There were insufficient data to compare
performance of the ELISPOT-based IGRA with the TST or ELISA-based IGRA.
Limitations: 17 of 47 included studies (36.2%) did not contain sufficient data to contribute to meta-analysis.
Conclusions: Compared to the TST, the ELISA-based IGRA was associated more strongly with risk factors
for latent TB in end-stage kidney disease.
Am J Kidney Dis. 61(1):33-43. © 2012 by the National Kidney Foundation, Inc.
INDEX WORDS: Latent tuberculosis; tuberculin skin test; QuantiFERON; T-SPOT.TB; end-stage kidney
disease; systematic review; dialysis; transplantation.Uremia in end-stage kidney disease contributes togeneralized immune dysfunction that results in
increased susceptibility to infectious diseases, includ-
ing tuberculosis (TB).1,2 Individuals with end-stage
kidney disease are up to 50 times more likely to
develop active TB than the general population, and
mortality is high, between 17% and 75%.3 A recent
study in Australia reported an incidence of active TB
in people on dialysis therapy of 66.8 cases/100,000
persons per year and an adjusted relative risk of 7.87
compared with the general population.4 Accurate and
timely diagnosis and treatment of latent TB is key to
preventing active disease, but is hampered by limita-
tions in gold-standard diagnostic tests for determining
true latent TB status.5 Although prophylaxis with
anti-TB medications is effective in preventing ac-
tive disease, anti-TB medications also are associ-
ated with hepatitis, neurotoxicity, and significant
Am J Kidney Dis. 2013;61(1):33-43drug-drug interactions.6-9 Screening patients for
latent TB can be used to target prophylaxis to
patients at the highest risk of developing active TB
while avoiding unnecessary complications of treat-
ment in low-risk individuals.
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Rogerson et alUntil recently, the detection of latent TB has relied
on the tuberculin skin test (TST). Utility of the TST in
clinical practice is limited by poor sensitivity in immu-
nocompromised people and poor specificity in BCG-
vaccinated people.10 An alternative to the TST are
interferon  release assays (IGRAs), in which inter-
feron  (an indicator of antimycobacterial effector T
cells) can be assayed by ELISA (enzyme-linked immu-
nosorbent assay; eg, the QuantiFERON tests [Celles-
tis] or ELISPOT (enzyme-linked immunosorbent spot;
eg, the T-SPOT.TB [Oxford Immunotec]). These in
vitro assays measure the response of sensitized T cells
to mycobacterial antigens (early secretory antigenic
target 6 [ESAT-6] and culture filtrate protein 10) in
whole blood.
National guidelines for the diagnosis of latent TB
are inconsistent.11,12 Some guidelines offer no spe-
cific recommendation for test use,13 some propose
that IGRAs should be used after a negative TST
result,14,15 and others recommend that IGRAs replace
the TST. No specific guidelines exist for the end-stage
kidney disease population; however, current recom-
mendations from the United Kingdom indicate the use
of IGRAs with or without a TST in people with
chronic kidney disease.16 The few guidelines that
exist for immunosuppressed populations (excluding
human immunodeficiency virus [HIV] populations)
also are conflicting. Canadian guidelines for immuno-
suppressed persons recommend using the TST with or
without a supplementary IGRA,14 whereas the United
Kingdom and Switzerland recommend replacing the
TST with an IGRA.17,18
Determining the diagnostic accuracy of IGRAs in
end-stage kidney disease using epidemiologic first
principles is problematic because the existing stan-
dard test (TST) performs poorly and therefore makes
direct comparison invalid. Previous systematic re-
views of IGRA test performance are limited to the
general population and most use 2 separate popula-
tions of people to estimate sensitivity (a population
including only active TB cases) and specificity (a
population of healthy low-risk people).19-21 An alter-
native approach is to measure the association of test
positivity with medical evidence of TB infection and
epidemiologic risk factors.22 A pretest clinical risk
assessment encompassing a person’s risk of exposure,
other comorbid conditions, and radiologic imaging
may help interpret the validity of a positive or nega-
tive result. A test that is both sensitive and specific for
latent TB should have test positivity closely associ-
ated with risk factors such as old TB on chest radio-
graph, previous treatment for active TB, contact with
an active case of TB, high-risk nationality, and immu-
nosuppression (other than uremic related).
34Given the paucity of evidence-based guidance for
clinical decision making, we aimed to systematically
review all studies that assessed the association of TST
or IGRA results with clinical risk factors for latent TB
in people with end-stage kidney disease.
METHODS
Inclusion/ExclusionCriteria
We included all studies in any language that reported the
performance of any diagnostic test for latent TB in conjunction
with either medical evidence or clinical risk factors in adults or
children with end-stage kidney disease. We excluded studies that
included patients with end-stage kidney disease with active TB at
the time of testing when data could not be separated from patients
without active TB.
Search Strategy
We searched MEDLINE and EMBASE from inception to
October 2010. Articles were located using a search strategy
composed of 3 filters, the first for test terms, the second for
people with end-stage kidney disease, and the third for TB
terms. The full search strategy is shown in Table S1 (available
as online supplementary material). We also searched conference
proceedings, including Australian Society for Microbiology
2005-2010, Australian Society for Infectious Diseases 2007-
2010, Infectious Diseases Society of America 2007-2010, Inter-
science Conference on Antimicrobial Agents and Chemo-
therapy 2005-2010, European Congress of Clinical Microbiology
and Infectious Diseases 2005-2010, American Society for Mi-
crobiology 2010, and International Congress on Infectious
Diseases 2008-2010. The search was conducted by hand, or
when electronic copies were available, we searched on the
following text terms: tuberculosis, interferon, QuantiFERON,
QFT, TSPOT.TB, ELISPOT, tuberculin skin test, TST, haemodi-
alysis, and hemodialysis.
DataAbstraction
Data were abstracted from studies by 3 investigators working
independently, using standardized data abstraction forms. We
collected data for study setting and design, participant character-
istics, risk factors for latent TB, test details, and test results. We
investigated both medical and epidemiologic risk factors for
latent TB (Table S2). Medical risk factors included a positive
chest radiograph for past TB, previous active TB or prophylac-
tic treatment for TB, and any iatrogenic or disease-related
immunosuppression (other than uremia related). Epidemiologic
risk factors included nationality and contact with a person with
active TB (documented by a health care professional or self-
reported). We also investigated BCG vaccination status as a
protective factor. Study quality was assessed with an adapted
version of the QUADAS (Quality Assessment of Diagnostic
Accuracy Studies) tool (Table S3).23 This tool consists of 14
methodological items that assess study validity in terms of
appropriateness of patient spectrum and reference standard,
bias, test execution, loss to follow-up, and indeterminate re-
sults.
Statistical Analysis
Study setting, patient characteristics, and QUADAS tool data
were summarized descriptively. When sufficient data were
available, we constructed 22 tables and calculated odds ratios
(ORs; with 95% confidence intervals [CIs]) for test positivity
with each risk factor. When all patients in a study had a risk
Am J Kidney Dis. 2013;61(1):33-43
Tests for Latent TB in ESKDfactor or all patients with a risk factor had the same result, we
added 0.5 to each cell of the 22 table to calculate the OR.24 In
studies that assessed 2 or more tests in the same population, we
compared the association of test positivity with risk factor
between tests as a relative diagnostic OR (relative OR [ROR]
with 95% CIs). Variance was calculated using a previously
published method that assumes a correlation between tests of
0.5, producing conservative estimates.22 Statistical significance
was tested with a Wald test and reported as a P value. Forest
plots and summary estimates for ORs and RORs were generated
in STATA 11.2 (StataCorp, www.stata.com) using a random-
effects model weighted by inverse variance. Between-study
heterogeneity was assessed using the I2 statistic, which reports
the percentage of variation across studies that is due to true
heterogeneity rather than chance.
SensitivityAnalysis
To test the robustness of our results against interstudy heteroge-
neity, we conducted sensitivity analyses using random-effects
meta-regression. Specifically, we compared studies of dialysis
patients alone versus transplantation/mixed populations of dialy-
sis and transplantation patients, studies that used blinding of
test interpretation to other test results versus those that did not
use blinded interpretation, studies that used a TST cutoff of 5
versus 10 mm, and studies that used second- versus third-
generation QuantiFERON tests.
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Figure 1. Results of the literature
search for studies reporting test perfor-
mance and risk-factor assessment for la-
tent tuberculosis (TB) in people with end
stage kidney disease (ESKD). Abbrevia-
tions: ELISA, enzyme-linked immunosor-
bent assay; ELISPOT, enzyme-linked im-
munosorbent spot; IFN-, interferon ;
TST, tuberculin skin test. †  yrtemotyC wolFSee Table S4for study details.
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Studies Identiﬁed
Our search identified 949 potential citations: 937
citations were identified in electronic databases, 9 cita-
tions were identified in conference proceedings, 1 citation
came from reference list searches, and 1 citation came
from an expert in the field (Fig 1). In total, 47 studies
(6,828 participants) were included; however, only 30
studies (4,546 participants) contained sufficient data
to contribute to meta-analysis.
Characteristics of included studies that contributed
to meta-analysis are listed in Table 1. In general,
studies were conducted mostly in dialysis patients
(23/30 [76.7%]) and in countries with low (5 cases/
100,000) to moderate (50 cases/100,000) TB preva-
lence.25 The study setting was primarily outpatient
dialysis clinics and all studies were prospective. Two
studies (306 participants) were conducted as contact
investigations in response to possible TB expo-
sure.26,27 Seventeen studies (2,903 participants) evalu-
ated the TST only, 9 studies (1,126 participants)
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Rogerson et aldirectly compared an IGRA to the TST, and the other
4 studies (517 participants) evaluated flow cytometry
or antibody detection (eg, MycoDot, Determiner TBGL
Antibody) kits.
Characteristics of included studies that did not
provide sufficient data to contribute to meta-analysis
are listed in Table S4. Six studies directly compared
the TST and an IGRA, 7 studies evaluated the TST
only, 3 studies evaluated an ELISA-based IGRA only,
and 1 study evaluated flow cytometry. These studies
included 2,282 participants, of whom 1,258 were on
Table 1. Character
Study Test Evaluation Country No
Dialysis
Inoue et al28 (2009) TST vs QFT JP 15
Lee et al29,30 (2010) TST vs QFT TW 9
Seyhan et al31 (2010) TST vs QFT TR 10
Kim et al32,33 (2010) TST vs T-SPOT.TB KR 20
Chung et al34 (2010) TST vs QFT vs T-SPOT.TB KR 16
Triverio et al35 (2009) TST vs QFT vs T-SPOT.TB CH 6
Lee et al36,37 (2009) TST vs QFT vs T-SPOT.TB TW 3
Eleftheriadis et al38 (2005) TST vs Ab detection GR 9
Yanai et al39 (2006) TST vs Ab detection JP 24
Wauters et al40 (2004) TST BE 22
Shankar et al41 (2005) TST IN 10
Fang et al42 (2002) TST TW 17
Yildiz et al43,44 (1998) TST TR 2
Ates et al45,46 (2010) TST TR 77
Habesoglu et al47 (2007) TST TR 18
Taskapan et al48 (2000) TST TR 3
Dogan et al49 (2005) TST TR 12
Cengiz & Seker50 (2006) TST TR 10
Woeltje et al51 (1998) TST US 30
Smirnoff et al52 (1998) TST US 5
Hickstein27 (2007) TST US 21
Linquist et al26 (2002) TST US 9
Poduval & Hammes53 (2003) TST US 11
Transpla
Sester et al54 (2006) TST vs Flow cytometry DE 11
Sester et al55 (2009) Flow cytometry DE 6
Mixed Dialysis and
Passalent et al56 (2007) TST vs T-SPOT.TB CA 20
Winthrop et al57 (2008) TST vs QFT vs T-SPOT.TB US 10
Kantarci et al58 (2006) TST TR 16
Aydogan et al59 (2009) TST TR 15
Basoglu et al60 (2006) TST TR 4
Note: Unless otherwise indicated, values shown as number (percentage
Abbreviations and definitions: Ab, antibody; BCG, bacille Calmette-Gu
kidney disease; GR, Greece; IN, India; JP, Japan; KR, South Korea; NR,
ELISPOT-based TB test; TST, tuberculin skin test; TW, Taiwan; US, Unite
aNational prevalence of TB in year of study publication, given as cases p
bNot specified.
cTB prevalence in Taiwan estimated from data for China.dialysis therapy, 820 had undergone transplantation,
36and the other 204 were not specified. Age and time
spent on treatment of participants were similar be-
tween studies that contributed to meta-analysis and
those that did not. Data for BCG vaccination rate were
limited.
Results of the study quality assessment are shown
in Fig 2. Overall, the quality of studies included in the
review was suboptimal and often insufficient detail
was available to make a judgment about potential
bias. The method of patient recruitment was unclear
in most studies (46/47 [97.8%]). Blinding of test
of Included Studies
le Sex Age (y)
ESKD
Treatment
(mo)
BCG
Vaccinated
(%) TB Prevalencea
ulation
(59.9) 65.4  65 42.4  NR NRb 74.6 (8.3-46.0)
(37.6) 58.3  14.9 72.0 61.3 137.0 (56.0-225.0)c
(47.0) 56.2 15.3 NR 67.0 41.0 (15.0-71.0)
(72.2) NR NR NR 115.0 (38.0-197.0)
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Tests for Latent TB in ESKDclinical risk factors also was predominately unclear
(20/47 [42.6%] and 45/48 [95.7%], respectively). Risk-
factor assessment and test procedures generally were
described in sufficient detail to repeat the studies
(30/47 [63.8%] and 41/47 [87.2%], respectively).
Clinical risk assessment was considered comprehen-
sive in 37 of 47 studies (78.7%). Few studies reported
unexplainable indeterminate results or participant with-
drawals. Study quality was poor but not different
across studies that contributed to meta-analysis and
those that did not; see Fig S1 for quality assessment of
only studies that contributed to meta-analysis.
Associationof Test PositivityWithClinical Risk Factors
Overall, positive test results for latent TB as mea-
sured by ELISA-based IGRA, ELISPOT-based IGRA,
and TST were associated significantly with a medical
history of TB infection (ELISA IGRA: OR, 6.01 [95%
CI, 2.66-13.56; P  0.001]; ELISPOT IGRA: OR,
5.02 [95% CI, 2.13-11.87; P 0.001]; TST: OR, 1.95
[95% CI, 1.17-3.23; P  0.01]). A positive ELISA
IGRA was associated strongly with radiologic evi-
dence of TB infection (OR, 2.97; 95% CI, 1.30-6.82;
P  0.01) and contact with a case of active TB (OR,
3.52; 95% CI, 1.69-7.31; P  0.001). In contrast,
there was insufficient evidence to determine the direc-
tion of association of a positive TST result with
radiologic evidence of TB infection (OR, 0.79; 95%
CI, 0.90-3.25; P  0.7) or contact with a case of
active TB (OR, 0.88; 95% CI, 0.43-1.82; P  0.7).
The direction of association of a positive ELISPOT
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Figure 2. Methodological quality of studies included in revi
Accuracy Studies) elements. (1) Generalizability of test results to
selection method adequate (selection bias); (3) comprehensive ri
testing and risk-factor assessment (disease progression bias); (5
the same tests (differential verification bias); (7) risk-factor asses
in sufficient detail to repeat (repeatability); (9) risk-factor assess
interpretation conducted without knowledge of other test results (
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Am J Kidney Dis. 2013;61(1):33-43and contact with a case of active TB also was unclear
(ORs of 1.88 [95% CI, 0.43-8.22; P  0.4] and 1.42
[95% CI, 0.80-2.52; P  0.2], respectively). There
was insufficient evidence to determine the direction of
association of test positivity with high-risk national-
ity, immunosuppression, and BCG vaccination for all
tests (Figs S2-S7). Comparing studies that blinded test
interpretation to information about clinical risk fac-
tors with those that did not or were unclear, we found
no significant differences in association of test positiv-
ity for radiologic evidence of TB, medical evidence of
TB, contact with active TB, immunosuppression, or
nationality (P  0.5). The OR for the association of
TST positivity with BCG vaccination was signifi-
cantly higher in unblinded studies (2.04; 95% CI,
1.18-3.53) compared with blinded studies (0.63; 95%
CI, 0.27-1.46; P 0.05). A significant difference also
was found in the association of a positive TST result
with immunosuppression when studies were stratified
by modality of end-stage kidney disease treatment.
The summary OR was higher in studies of dialysis
patients (OR, 1.38; 95% CI, 0.98-1.94) than transplan-
tation and mixed populations (OR, 0.38; 95% CI,
0.22-0.67; P  0.004). There were no significant
differences for other risk factors when studies were
stratified by modality of end-stage kidney disease
treatment (P  0.1). Our findings also were un-
changed when we compared studies using a TST
cutoff of 5 versus 10 mm (P  0.1) and those that
used second- versus third-generation ELISA IGRAs
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Clinical Risk Factors
Figures 3-5 show the direct comparison between
IGRAs and TST results for association of test positiv-
ity with clinical risk factors. From the findings of 6
studies, compared to a positive TST result, a positive
ELISA IGRA result was associated more strongly
with radiologic evidence of past TB (ROR, 4.29; 95%
CI, 1.83-10.03; P  0.001) and contact history with
active TB (ROR, 3.36; 95% CI, 1.61-7.01; P 0.001;
Fig 3). Conversely, a positive ELISA IGRA result was
associated less strongly with BCG vaccination com-
pared to a positive TST result (ROR, 0.30; 95% CI,
0.14-0.63; P  0.002; Fig 3). There was no evidence
of a difference in association of test positivity with
high-risk nationality (ROR, 2.25; 95% CI, 0.53-9.61;
P  0.3) or medical history of TB (ROR, 2.68; 95%
CI, 0.97-7.43; P  0.06) between the ELISA IGRA
and TST results. Data from 6 studies comparing
performance of the ELISPOT IGRA and TST showed
there was no evidence of a difference between the
association of a positive ELISPOT IGRA or TST
.
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38Four studies compared the ELISA and ELISPOT
IGRAs directly. One study reported a positive
ELISPOT IGRA result to be associated more strongly
with radiologic evidence of past TB than a positive
ELISA IGRA result (ROR, 0.11; 95% CI, 0.02-0.77;
P  0.03). No evidence of a difference was found for
any of the other risk factors (Fig 5). These results
were robust to heterogeneity in TST cutoff (P  0.3),
ELISA IGRA generation (P  0.5), and modality of
end-stage kidney disease treatment (P 0.3).
Comparisons ofOther Tests for Latent TB
Two studies evaluated flow cytometry; one evalu-
ated both ESAT-6 and Tuberkulin GT 100 as stimulat-
ing antigens, and the other evaluated only ESAT-
6.38,39 All transplant recipients were assumed to be
immunosuppressed. There was no significant associa-
tion between flow cytometry positivity (using Tuberku-
lin GT 100 or ESAT-6 as the stimulating agent) and
immunosuppression (ORs of 1.36 [95% CI, 0.08-
22.13; P  0.8] and 0.43 [95% CI, 0.01-22.46; P 
0.7], respectively; Fig S6). In one study, the TST also
was evaluated; however, no difference in association
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Figure 3. Tuberculin skin
test (TST) versus enzyme-
linked immunosorbent as-
say interferon  release as-
say (QuantiFERON): relative
association of a positive test
with risk factors for latent tu-
berculosis. Abbreviations:
CI, confidence interval;
ROR, relative odds ratio.40
mmonwith immunosuppression was found between flow
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e TST
Tests for Latent TB in ESKDcytometry (using either ESAT-6 or Tuberkulin GT
100) and TST (RORs of 4.58 [95% CI, 0.09-244.796;
P  0.5] and 1.80 [95% CI, 0.033-98.112; P  0.8],
respectively). Two studies evaluated antibody detec-
tion kits. In one study, both MycoDot and Determiner
TBGLAntibody test positivity were associated signifi-
cantly with radiologic evidence of past TB (ORs of
3.47 [95% CI, 1.33-9.07; P 0.01] and 2.18 [95% CI,
1.04-4.59; P  0.04], respectively). The other study,
which evaluated MycoDot only, showed no signifi-
cant association of test positivity with BCG vaccina-
tion (OR, 0.44; 95% CI, 0.01-22.61; P 0.7).
DISCUSSION
Screening for latent TB in the end-stage kidney
disease population allows treatment to be targeted at
persons with the highest risk of active TB and who
will benefit most from prophylaxis. The key finding of
this review is that compared to the TST, ELISA IGRA
positivity was associated more strongly with clinical
risk factors for latent TB, while associated less strongly
with prior BCG vaccination. This suggests that ELISA
IGRA is both more sensitive and specific than the TST
in the context of end-stage kidney disease. Global
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Figure 4. Tuberculin skin
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linked immunosorbent spot
interferon release assay (T-
SPOT.TB): relative associa-
tion of a positive test result
with risk factors for latent tu-
berculosis. Abbreviations: CI,
confidence interval; ROR,
relative odds ratio.guidelines for latent TB screening in immunocompro-
Am J Kidney Dis. 2013;61(1):33-43mised populations currently recommend using an
IGRA as a supplementary or replacement test to the
TST.11 The results of this review support replacement
of the TST with the ELISA IGRA. Not enough data
were available for the relative performance of
ELISPOT IGRA with the TST or ELISPOT IGRA
with ELISA IGRA to make conclusions about the
ELISPOT IGRA.
Data analyzed in the present study were restricted
largely to the dialysis population (3,700/4,546
[81.4%]). Although this may be considered a limita-
tion, performance of tests for latent TB in the dialysis
population is most clinically relevant because assess-
ment for latent TB generally occurs prior to starting
dialysis therapy or during clinical evaluation leading
up to kidney transplantation.61
Compared with both the TST and ELISPOT IGRA,
the ELISA IGRA showed the strongest overall associa-
tion with clinical risk for latent TB, including radio-
logic evidence of past TB (OR, 2.97; Fig S2), medical
evidence of past TB (OR, 6.01; Fig S3), and contact
with a person with active TB (OR, 3.52; Fig S4). Data
were less conclusive for the utility of the ELISPOT
IGRA, although positive results from this assay were
0.18 (0.02, 1.33)
3.42 (0.54, 21.59)
0.57 (0.09, 3.46)
0.73 (0.14, 3.81)
3.90 (0.67, 22.76)
1.67 (0.30, 9.19)
2.52 (0.74, 8.57)
1.60 (0.22, 11.81)
0.73 (0.17, 3.05)
2.20 (0.53, 9.20)
1.33 (0.54, 3.28)
2.15 (0.04, 114.92)
5.11 (0.10, 262.62)
4.81 (0.09, 247.21)
1.38 (0.21, 8.88)
1.81 (0.83, 3.96)
1.86 (0.94, 3.71)
0.10 (0.02, 0.60)
0.77 (0.20, 3.04)
0.73 (0.23, 2.37)
0.45 (0.14, 1.40)
ROR (95% CI)
31.56
33.91
34.52
100.00
48.31
51.69
100.00
20.39
39.81
39.81
100.00
3.00
3.06
3.06
13.69
77.20
100.00
25.73
34.52
39.74
100.00
Weight
%
1.25 .5 10 20 40
More common with positive TSPOT.TB098)
98)
53)
65)
142)associated with medical evidence of past TB (OR,
39
sitive
Rogerson et al5.02; Fig S3). We found no association between
nationality and test positivity for any of the tests;
however, in these analyses, data were limited to stud-
ies conducted in countries with low to moderate TB
burden. The clinical value of IGRAs for detecting
latent TB in different patient populations in high-
prevalence regions warrants study.
Studies that met the inclusion criteria but did not
provide sufficient data to contribute to meta-analysis
represent a potential source of bias in this review.
These studies accounted for 36.2% (17/47) of in-
cluded studies and 33.4% (2,282/6,828) of all partici-
pants. Due to missing data for study design and
patient characteristics, it was not possible to formally
compare differences between studies that contributed
to meta-analysis and those that did not (Table 1; Table
S4). The available data suggest that patient character-
istics within the dialysis and transplantation popula-
tions are similar between studies that contributed to
meta-analysis and those that did not, but there appear
to be proportionately more transplant recipients in
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40Another key finding of the present study is that
based on the best available evidence, the preferred
IGRA for diagnosing latent TB is the ELISA IGRA,
although comparison of either the ELISA or ELISPOT
IGRAs with the TST and each other was limited by
the small number of evaluable studies (n10 for each
comparison; Figs 3-5). Data from 6 studies indicate
that compared to the TST, ELISA IGRA positivity
was associated more strongly with clinical risk factors
for latent TB, whereas comparing ELISPOT IGRA
and TST, no statistical differences were observed in
ROR for any clinical risk factors.32,34-36,56,57 Only a
single study of 4 studies comparing the performance
of ELISPOT and ELISA IGRAs in end-stage kidney
disease showed that the former was associated more
strongly with radiologic evidence of past TB.35
Although the utility of assays other than the ELISA
IGRA, TST, and ELISPOT IGRA have been studied
in the context of diagnosing latent TB, neither sero-
logic detection of antibody to Mycobacterium tubercu-
losis or flow cytometry studies have been shown to be
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leasclinically useful and sensitivity analyses have been
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Tests for Latent TB in ESKDlimited by the small number of reports.10,38,39,54,55
Based on the present available data, these assays
cannot be recommended for assisting in the diagnosis
of latent TB.
Systematic reviews are the preferred format for
summarizing evidence because they use explicit and
reproducible methods to limit bias. We acknowledge
that the validation of test results against clinical risk
factors has several limitations. Although this ap-
proach allows us to make inferences about the accu-
racy of tests in relative terms, it does not allow us to
calculate absolute measures of test accuracy. To de-
rive test accuracy characteristics, previous reviews in
the general population have overcome the lack of a
reference standard by using active TB and low-risk
individuals as surrogates for positive and negative
latent TB status.19-21 This method is dubious because
active and latent TB are distinct disease states that
elicit different responses from the host immune sys-
tem and therefore it may be inappropriate to use active
TB as an immunologic model for latent TB.1,62 Sev-
eral studies have shown that responses to the TST and
IGRAs diminish during untreated active TB infection,
but rapidly increase after treatment, suggesting that
active TB may suppress the host immune response to
these tests.63-66
Another limitation of this review is that the implica-
tions of our results rely on the assumption that a high
proportion of people with clinical risk factors for
latent TB actually have latent TB. Although this
assumption is difficult to prove given the lack of a
reference standard for latent TB, there is evidence that
active TB is more likely to develop in dialysis patients
with old TB on chest radiograph or immunosuppres-
sive diseases, including diabetes mellitus and HIV
infection.67 Risk factors for the transmission of latent
TB also may be inaccurate and difficult to quantify
and therefore a potential source of heterogeneity be-
tween studies.22 For example, studies included in this
review assessed contact with active TB as a dichoto-
mous risk factor only, whereas from epidemiologic
studies, we know that the likelihood of transmission is
determined by both time and proximity to a person
with active TB.22 Assessing nationality as a dichoto-
mous risk factor is similarly problematic because it
assumes that all individuals from a country with high
TB burden have the same risk of transmission, whereas
in reality, transmission requires an interplay of several
factors, including socioeconomic status, time spent in
the country, and where in the country that time was
spent.
Future research in this area should pursue 3 direc-
tions. First, this review demonstrated a gap in evi-
dence for the relative test performance of the ELISA
and ELISPOT IGRAs. More studies are required to
Am J Kidney Dis. 2013;61(1):33-43assess the relative performance of these tests in the
end-stage kidney disease population. Second, a study
assessing the active TB rate in patients after test-
directed treatment would be helpful to derive the
relative clinical value of the TST and ELISA and
ELISPOT IGRAs. Third, a cost-effectiveness evalua-
tion is needed to determine whether the reduction in
false-positive and negative results that occurs when
ELISA IGRA replaces the TST is worth the trade-off
in any cost increase that also may occur.
In conclusion, we determined that compared to
the TST, ELISA IGRA positivity was associated
more strongly with clinical risk factors for latent
TB in end-stage kidney disease and therefore is
likely to be a more accurate diagnostic tool for latent
TB in end-stage kidney disease. This finding is consis-
tent with previous systematic reviews conducted in
the general population that showed that IGRA results
correlate better with the intensity of TB exposure
compared to the TST while remaining independent of
BCG vaccination status22 and that IGRAs are more
sensitive and specific and thus the preferred tests.19-21
On the basis of best available evidence, we propose
that the ELISA IGRA should be the test of choice for
screening for latent TB, and a review of clinical
practice guidelines for managing latent TB in the
end-stage kidney disease population is warranted.
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